◆

Subtypes

4

Polygenic Hypercholesterolemia

Common LDL-C-raising trait driven by the cumulative effect of multiple common variants plus dietary and metabolic modifiers, causing isolated hypercholesterolemia without a single high-penetrance Mendelian cause.

Familial Combined Hyperlipidemia

Common genetic lipid disorder characterized by elevated total cholesterol, LDL cholesterol, and/or triglycerides, with variable phenotypic expression among affected family members.

Hypertriglyceridemia

Elevation of triglyceride levels, which may be primary (genetic) or secondary to conditions such as obesity, diabetes, or alcohol use.

Show evidence (1 reference)

DOI:10.3390/ijms25126364 SUPPORT Human Clinical

"The risk for coronary heart diseases varies from 57 to 76% in patients with hypertriglyceridemia."

This review confirms the cardiovascular impact of hypertriglyceridemia.

Mixed Hyperlipidemia

Simultaneous elevation of both cholesterol and triglycerides, often associated with increased cardiovascular risk.

⚙

Pathophysiology

8

Impaired Hepatic ApoB-Containing Lipoprotein Clearance

Reduced hepatic clearance of LDL and related apoB-containing lipoproteins due to partial LDLR-pathway insufficiency, increased PCSK9 activity, and other polygenic or metabolic perturbations. In this complex-trait context, the pathway is usually impaired by combined common-variant and environmental effects rather than a single receptor gene defect.

Hepatocyte link

LDLR link APOB link PCSK9 link

Receptor-mediated endocytosis link Cholesterol metabolic process link

Downstream

Oxidized LDL Infiltration of Arterial Intima Persistently elevated circulating LDL increases arterial wall exposure to atherogenic lipoproteins.

Show evidence (2 references)

DOI:10.1038/s41467-024-46336-2 SUPPORT Model Organism

"Proprotein convertase subtilisin/kexin type-9 (PCSK9) binds to and degrades low-density lipoprotein (LDL) receptor, leading to increase of LDL cholesterol in blood."

Confirms that LDL receptor degradation by PCSK9 leads to impaired LDL clearance and elevated LDL-C levels.

PMID:28444290 SUPPORT Human Clinical

"Rare genetic mutations that cause reduced LDL receptor function lead to markedly higher LDL-C and a dose-dependent increase in the risk of ASCVD, whereas rare variants leading to lower LDL-C are associated with a correspondingly lower risk of ASCVD."

Rare LDLR-pathway perturbations establish impaired hepatic LDL clearance as a core hypercholesterolemic mechanism that also informs common LDL-C elevation.

PCSK9-Mediated LDL Receptor Degradation

PCSK9 binds to LDL receptors on the hepatocyte surface and promotes their lysosomal degradation, reducing receptor recycling and the number of receptors available for LDL clearance. Increased PCSK9 activity, whether genetically determined or acquired, can raise LDL-C. PCSK9 also directly induces inflammation independently of the LDL receptor via CAP1-mediated NF-kB signaling.

Hepatocyte link Macrophage link Endothelial cell link

PCSK9 link

Receptor-mediated endocytosis link Inflammatory response link

Downstream

Impaired Hepatic ApoB-Containing Lipoprotein Clearance PCSK9-driven LDLR degradation lowers receptor availability and impairs LDL clearance.

Show evidence (2 references)

DOI:10.1038/s41467-024-46336-2 SUPPORT Model Organism

"PCSK9 itself directly induces inflammation and aggravates atherosclerosis independently of the LDL receptor."

Demonstrates that PCSK9 has LDLR-independent pro-inflammatory functions, contributing to atherosclerosis beyond its role in LDL receptor degradation.

DOI:10.1038/s41467-024-46336-2 SUPPORT Model Organism

"Adenylyl cyclase-associated protein 1 (CAP1) is the main binding partner of PCSK9 and indispensable for the inflammatory action of PCSK9, including induction of cytokines, Toll like receptor 4, and scavenger receptors, enhancing the uptake of oxidized LDL."

Identifies the CAP1-mediated signaling pathway through which PCSK9 promotes inflammation and foam cell formation.

Dysregulated Hepatic Lipogenesis and VLDL Overproduction

Increased de novo lipogenesis in the liver driven by insulin resistance and transcription factor SREBP-1c activation leads to overproduction of VLDL particles, contributing to elevated triglycerides and small dense LDL. VLDL assembly depends on apoB lipidation by microsomal triglyceride transfer protein (MTP) in the rough endoplasmic reticulum.

Hepatocyte link

Lipid biosynthetic process link Lipid metabolic process link

Downstream

Impaired Lipoprotein Lipase Activity and ApoC-III Dysregulation Increased VLDL output increases dependence on LPL-mediated triglyceride-rich lipoprotein processing.

Show evidence (1 reference)

DOI:10.1186/s12944-023-01993-y SUPPORT Other

"Preclinical investigations have revealed that interventions targeting VLDL production or promoting VLDL metabolism, independent of the LDL receptor, can potentially decrease cholesterol levels and provide therapeutic benefits."

Confirms that VLDL production is a key therapeutic target in hyperlipidemia and that VLDL overproduction contributes to elevated cholesterol levels.

Impaired Lipoprotein Lipase Activity and ApoC-III Dysregulation

Deficiency or dysfunction of lipoprotein lipase (LPL) impairs hydrolysis of triglyceride-rich lipoproteins (chylomicrons and VLDL) in capillary endothelium, resulting in severe hypertriglyceridemia. Apolipoprotein C-III (ApoC-III) is a key inhibitor of LPL and also reduces hepatic uptake of triglyceride-rich lipoprotein remnants, contributing to hypertriglyceridemia and cardiovascular risk.

LPL link APOC3 link

Lipid metabolic process link

Downstream

Oxidized LDL Infiltration of Arterial Intima Persistent accumulation of triglyceride-rich remnants contributes to atherogenic lipoprotein burden in arterial walls.

Show evidence (2 references)

DOI:10.1007/s11883-023-01080-8 SUPPORT Human Clinical

"ApoC-III has been recently considered an important player in insulin resistance mechanisms, lipodystrophy, diabetic dyslipidemia, and postprandial hypertriglyceridemia"

Confirms the central role of ApoC-III in triglyceride metabolism dysregulation and its broader cardiometabolic effects.

DOI:10.1007/s11883-023-01080-8 SUPPORT Human Clinical

"the inhibition of ApoC-III is a promising therapeutical strategy for the management of severe hypertriglyceridemia and in CVD prevention"

Validates ApoC-III as a key pathogenic molecule in hypertriglyceridemia.

Oxidized LDL Infiltration of Arterial Intima

Oxidized LDL infiltrates and accumulates in the arterial intima, establishing the initiating lipid milieu for atherogenesis.

Endothelial cell link

Inflammatory response link

Downstream

Macrophage Recruitment to Arterial Intima Intimal oxidized LDL promotes leukocyte attraction and macrophage influx.

Show evidence (1 reference)

PMID:30165986 SUPPORT Human Clinical

"Because atherogenic lipoproteins play a central causal role in the initiation and progression of atherosclerosis, maintaining optimal lipid levels is necessary to achieve ideal cardiovascular health."

Supports oxLDL-associated lipoprotein burden as an initiating event in atherosclerosis.

Macrophage Recruitment to Arterial Intima

Inflammatory signaling within lipid-rich intima recruits macrophages to arterial lesions.

Macrophage link Endothelial cell link

Inflammatory response link

Downstream

Macrophage-Derived Foam Cell Formation Recruited macrophages internalize oxidized lipoproteins and transition toward foam cells.

Show evidence (1 reference)

DOI:10.3390/nu16132156 SUPPORT Human Clinical

"Disruption in any of these steps results in pathophysiological abnormalities such as dyslipidemia, obesity, insulin resistance, inflammation, atherosclerosis, peripheral artery disease, and cardiovascular diseases."

Supports inflammation-coupled transition from lipid imbalance to arterial immune-cell pathology.

Macrophage-Derived Foam Cell Formation

Macrophages in lipid-rich intima accumulate oxidized lipoproteins and differentiate into foam cells.

Macrophage-derived foam cell link Macrophage link

Macrophage-derived foam cell differentiation link

Downstream

Atherosclerotic Plaque Development Foam-cell accumulation drives fatty-streak maturation and plaque development.

Show evidence (1 reference)

DOI:10.1038/s41467-024-46336-2 SUPPORT Model Organism

"Adenylyl cyclase-associated protein 1 (CAP1) is the main binding partner of PCSK9 and indispensable for the inflammatory action of PCSK9, including induction of cytokines, Toll like receptor 4, and scavenger receptors, enhancing the uptake of oxidized LDL."

Supports enhanced oxidized-LDL uptake as a proximate mechanism for foam cell formation.

Atherosclerotic Plaque Development

Chronic intimal lipid retention and inflammation result in atherosclerotic plaque formation as a major end-organ consequence of sustained hyperlipidemia.

Endothelial cell link Vascular smooth muscle cell link

Inflammatory response link

Show evidence (2 references)

DOI:10.3390/nu16132156 SUPPORT Human Clinical

"Disruption in any of these steps results in pathophysiological abnormalities such as dyslipidemia, obesity, insulin resistance, inflammation, atherosclerosis, peripheral artery disease, and cardiovascular diseases."

Confirms the pathological link between lipoprotein dysregulation and atherosclerosis.

PMID:28444290 SUPPORT Human Clinical

"Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD."

The definitive EAS consensus statement establishing LDL as a causal factor in atherosclerotic cardiovascular disease.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

7

Cardiovascular 2

Premature Atherosclerosis FREQUENT Precocious atherosclerosis (HP:0004416)

Show evidence (1 reference)

PMID:28444290 SUPPORT Human Clinical

"any mechanism of lowering plasma LDL particle concentration should reduce the risk of ASCVD events proportional to the absolute reduction in LDL-C and the cumulative duration of exposure to lower LDL-C"

Establishes that cumulative LDL exposure drives atherosclerosis, explaining why familial hyperlipidemia with lifelong elevation causes premature disease.

Coronary Artery Disease FREQUENT Coronary artery atherosclerosis (HP:0001677)

Show evidence (1 reference)

DOI:10.3390/ijms25126364 SUPPORT Human Clinical

"The risk for coronary heart diseases varies from 57 to 76% in patients with hypertriglyceridemia."

Quantifies the high coronary heart disease risk in patients with hyperlipidemia.

Eye 1

Corneal Arcus OCCASIONAL Corneal arcus (HP:0001084)

Integument 1

Xanthomas OCCASIONAL Xanthomatosis (HP:0000991)

Metabolism 3

Elevated Triglycerides FREQUENT Hypertriglyceridemia (HP:0002155)

Show evidence (1 reference)

DOI:10.3390/ijms25126364 SUPPORT Human Clinical

"the higher the plasma concentrations in TGs, the higher the incidence and prevalence of death, myocardial infarction, and stroke."

Confirms the dose-dependent relationship between elevated triglycerides and adverse cardiovascular outcomes.

Decreased HDL Cholesterol FREQUENT Decreased HDL cholesterol concentration (HP:0003233)

Increased LDL Cholesterol VERY_FREQUENT Increased LDL cholesterol concentration (HP:0003141)

Show evidence (2 references)

PMID:28444290 SUPPORT Human Clinical

"Separate meta-analyses of over 200 prospective cohort studies, Mendelian randomization studies, and randomized trials including more than 2 million participants with over 20 million person-years of follow-up and over 150 000 cardiovascular events demonstrate a remarkably consistent..."

Establishes the dose-dependent association between LDL-C exposure and ASCVD risk.

DOI:10.5114/aoms/174743 SUPPORT Human Clinical

"almost 4 million deaths per year are attributed to LDL-C"

Demonstrates the massive global burden attributable to elevated LDL cholesterol.

🧬

Genetic Associations

6

LDLR (Monogenic Cause in Familial Hypercholesterolemia; Core LDL-C Clearance Pathway)

Autosomal Dominant

Show evidence (1 reference)

PMID:28444290 SUPPORT Human Clinical

"Rare genetic mutations that cause reduced LDL receptor function lead to markedly higher LDL-C and a dose-dependent increase in the risk of ASCVD"

Confirms that LDLR loss-of-function is sufficient to raise LDL-C and ASCVD risk, establishing the pathway as mechanistically central to hypercholesterolemia.

PCSK9 (Monogenic Cause in Familial Hypercholesterolemia and Modifier of LDL-C Burden)

Autosomal Dominant

Show evidence (1 reference)

DOI:10.1038/s41467-024-46336-2 SUPPORT Model Organism

"Proprotein convertase subtilisin/kexin type-9 (PCSK9) binds to and degrades low-density lipoprotein (LDL) receptor, leading to increase of LDL cholesterol in blood."

Confirms the canonical mechanism of PCSK9-mediated LDL receptor degradation.

APOB (Monogenic Cause and ApoB-Trafficking Determinant)

Autosomal Dominant

Show evidence (1 reference)

PMID:22417841 SUPPORT Human Clinical

"Autosomal dominant hypercholesterolemia (ADH) is commonly caused by mutations in the low-density lipoprotein (LDL) receptor gene (LDLR), in the apolipoprotein B-100 gene (APOB), or in the proprotein convertase subtilisin kexine 9 gene (PCSK9)."

Directly supports APOB as a canonical LDL-pathway gene whose perturbation can produce hypercholesterolemia.

LPL (Monogenic Cause in Severe Hypertriglyceridemia)

Autosomal Recessive

APOE (Lipoprotein Clearance Modifier)

APOC3 (Triglyceride-Rich Lipoprotein Modifier)

Show evidence (1 reference)

DOI:10.1007/s11883-023-01080-8 SUPPORT Human Clinical

"ApoC-III is clearly linked to cardiovascular disease (CVD) risk, and progression of coronary artery disease (CAD) as well as the calcification of aortic valve"

Confirms the pathogenic role of APOC3 in cardiovascular disease.

💊

Treatments

8

Statin Therapy

Action: targeted therapy Ontology label: Targeted Therapy NCIT:C93352

Agent: statin ↗

HMG-CoA reductase inhibitors that reduce hepatic cholesterol synthesis and upregulate LDL receptor expression, lowering LDL cholesterol by 30-50%.

Show evidence (2 references)

DOI:10.3390/nu16132156 SUPPORT Human Clinical

"Several medications are available for the treatment of dyslipoproteinemia. These include statins, fibrates, ezetimibe, niacin, PCSK9 inhibitors, evinacumab"

Lists statins as first-line pharmacotherapy for dyslipoproteinemia.

DOI:10.5114/aoms/174743 SUPPORT Human Clinical

"In 2023 there are still even 75% of patients over the LDL-C target, and hypercholesterolemia is the most common and the worst monitored CVD risk factor."

Highlights the ongoing need for effective statin therapy given high rates of uncontrolled LDL-C.

PCSK9 Inhibitors

Action: Pharmacotherapy NCIT:C15986

Agent: PCSK9 inhibitor ↗ alirocumab ↗ evolocumab ↗

Monoclonal antibodies (evolocumab, alirocumab) that block PCSK9 and increase hepatic LDL receptor recycling, producing potent LDL lowering.

Ezetimibe

Action: targeted therapy Ontology label: Targeted Therapy NCIT:C93352

Agent: ezetimibe ↗

Inhibits intestinal cholesterol absorption at the brush border via the NPC1L1 transporter, reducing LDL cholesterol when used alone or in combination with statins.

Fibrates

Action: Pharmacotherapy NCIT:C15986

Agent: fenofibrate ↗ gemfibrozil ↗

PPARalpha agonists that reduce triglyceride levels by enhancing fatty acid oxidation and lipoprotein lipase activity.

Lifestyle Modification

Action: dietary intervention MAXO:0000088

Dietary changes (reduced saturated fat, increased fiber), regular exercise, weight management, and smoking cessation as first-line interventions.

Omega-3 Fatty Acids

Action: Pharmacotherapy NCIT:C15986

Agent: omega-3 fatty acid ↗ icosapentaenoic acid ↗

High-dose EPA/DHA preparations reduce triglycerides by decreasing hepatic VLDL production.

Bempedoic Acid

Action: targeted therapy Ontology label: Targeted Therapy NCIT:C93352

Agent: bempedoic acid ↗

ATP citrate lyase inhibitor that reduces cholesterol biosynthesis upstream of HMG-CoA reductase, used in statin-intolerant patients.

ApoC-III Inhibitors

Action: Pharmacotherapy NCIT:C15986

Agent: antisense oligonucleotides ↗ olezarsen ↗

Antisense oligonucleotides such as olezarsen that reduce apolipoprotein C-III levels, significantly lowering triglycerides in patients with hypertriglyceridemia.

Show evidence (2 references)

DOI:10.1186/s12944-024-02297-5 SUPPORT Human Clinical

"Olezarsen is a GalNAc3-conjugated, hepatic-targeted antisense oligonucleotide that lowers apolipoprotein C-III (apoC-III) and triglyceride levels."

Describes the mechanism and clinical efficacy of the ApoC-III targeting antisense approach.

DOI:10.1186/s12944-024-02297-5 SUPPORT Human Clinical

"In the MD cohort, at Day 92 the percentage reduction in apoC-III/TG was − 81.6/ − 73.8% vs − 17.2/ − 40.8% reduction in placebo."

Demonstrates substantial triglyceride reduction achieved with ApoC-III inhibition in clinical trials.

🌍

Environmental Factors

3

High Saturated Fat Diet

Dietary intake of saturated and trans fats increases hepatic cholesterol synthesis and reduces LDL receptor expression, raising serum LDL cholesterol.

Show evidence (2 references)

PMID:28166253 SUPPORT Human Clinical

"Previous studies have shown that increases in LDL-cholesterol resulting from substitution of dietary saturated fat for carbohydrate or unsaturated fat are due primarily to increases in large cholesterol-enriched LDL, with minimal changes in small, dense LDL particles and apolipoprotein B."

Directly supports saturated-fat-driven LDL-C elevation.

PMID:37979064 SUPPORT Other

"Composition of nutrients, esp. fatty acids, influences lipid levels."

Supports nutrient composition, including fatty acids, as a modifiable driver of lipid abnormalities.

Sedentary Lifestyle

Physical inactivity is associated with reduced HDL cholesterol, elevated triglycerides, and impaired lipid metabolism.

Show evidence (2 references)

PMID:28748993 SUPPORT Human Clinical

"Per one hour increase in sedentary behavior there were significant adverse changes in glucose (4.79 mg/dl), insulin (2.73 pmol/l), HOMA-IR (0.75), BMI (0.69 kg/m²), waist circumference (1.95 cm), fat mass (1.03%), total cholesterol (9.73 mg/dl), HDL-cholesterol (-3.50 mg/dl), LDL-cholesterol..."

Quantifies adverse lipid changes (lower HDL and higher LDL/triglycerides) with increasing sedentary time.

PMID:28748993 SUPPORT Human Clinical

"The detrimental effect of sedentary behaviors on cardiometabolic and obesity-related traits is independent of physical activity levels."

Supports sedentary behavior as an independent environmental risk factor, not only the absence of exercise.

Obesity

Excess adiposity promotes insulin resistance, hepatic VLDL overproduction, and dyslipidemia characterized by elevated triglycerides and low HDL.

Show evidence (3 references)

DOI:10.3390/nu16132156 SUPPORT Human Clinical

"Disruption in any of these steps results in pathophysiological abnormalities such as dyslipidemia, obesity, insulin resistance, inflammation, atherosclerosis, peripheral artery disease, and cardiovascular diseases."

Links obesity to dyslipidemia and insulin resistance as interconnected metabolic abnormalities.

PMID:20563664 SUPPORT Human Clinical

"Higher BMI was inversely associated with HDL and directly associated with TG."

Direct human clinical evidence linking obesity severity to the characteristic high-TG/low-HDL dyslipidemia pattern.

PMID:37979064 SUPPORT Other

"Weight loss either with diet or antiobestic medication induces the decrease in triglycerides (TG) and LDL-C and the increase in HDL-C."

Supports a causal obesity-lipid relationship by showing lipid improvements following weight reduction.

🔬

Biochemical Markers

6

Total Cholesterol (Elevated)

Context: Elevated circulating cholesterol burden, typically reflecting increased apoB-containing lipoproteins in common hyperlipidemia phenotypes.

Show evidence (1 reference)

DOI:10.3390/nu16132156 SUPPORT Human Clinical

"Disruption in any of these steps results in pathophysiological abnormalities such as dyslipidemia, obesity, insulin resistance, inflammation, atherosclerosis, peripheral artery disease, and cardiovascular diseases."

Dyslipidemia, including elevated total cholesterol, is a primary manifestation of lipoprotein metabolism disruption.

LDL Cholesterol (Elevated)

Context: Core atherogenic lipid abnormality driving atherosclerotic cardiovascular risk in both monogenic and polygenic hyperlipidemia.

Show evidence (1 reference)

PMID:28444290 SUPPORT Human Clinical

"Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD."

Elevated LDL cholesterol is the central biochemical abnormality in hyperlipidemia and causally linked to ASCVD.

Triglycerides (Elevated)

Context: Elevated triglyceride-rich lipoproteins are common in mixed and insulin-resistant dyslipidemia and increase cardiometabolic risk.

Show evidence (2 references)

DOI:10.3390/ijms25126364 SUPPORT Human Clinical

"the higher the plasma concentrations in TGs, the higher the incidence and prevalence of death, myocardial infarction, and stroke."

Confirms triglyceride elevation as a key biochemical feature associated with cardiovascular outcomes.

PMID:30021845 SUPPORT Human Clinical

"Atherogenic dyslipidemia characterized by increased small LDL particle (LDL-P) concentration, rather than total LDL cholesterol content, along with elevated triglyceride-rich lipoproteins and low high-density lipoprotein (HDL) cholesterol (HDL-C), may be the primary lipid driver of PAD risk."

Supports triglyceride-rich lipoprotein elevation as a central component of atherogenic dyslipidemia.

HDL Cholesterol (Decreased)

Context: Reduced HDL-C commonly co-occurs with elevated triglyceride-rich lipoproteins in atherogenic dyslipidemia.

Show evidence (2 references)

PMID:30021845 SUPPORT Human Clinical

"Other features of atherogenic dyslipidemia, including elevations in TC:HDL-C, elevations in triglyceride-rich lipoproteins, and low standard and nuclear magnetic resonance-derived measures of HDL, were significant risk determinants."

Directly supports reduced HDL as part of the clinically relevant atherogenic dyslipidemia signature.

PMID:40489011 SUPPORT Other

"Decreased serum high-density-lipoprotein-cholesterol (HDL-C), HDL particles, and cell-cholesterol-efflux-capacity have all been associated with increased atherosclerotic cardiovascular disease (ASCVD) risk."

Summarizes independent HDL-related associations with ASCVD risk.

TC:HDL-C Ratio (Elevated)

Context: Composite atherogenic index integrating cholesterol burden and relative HDL deficiency.

Show evidence (1 reference)

PMID:30021845 SUPPORT Human Clinical

"In age-adjusted analyses, while LDL cholesterol was not associated with incident PAD, we found significant associations for increased total and small LDL-P concentrations, triglycerides, and concentrations of very LDL (VLDL) particle (VLDL-P) subclasses, increased total cholesterol (TC):HDL-C,..."

Provides quantitative cohort evidence that elevated TC:HDL-C tracks higher vascular event risk.

Apolipoprotein C-III (Elevated)

Context: hypertriglyceridemia

Show evidence (1 reference)

DOI:10.1007/s11883-023-01080-8 SUPPORT Human Clinical

"ApoC-III has been recently considered an important player in insulin resistance mechanisms, lipodystrophy, diabetic dyslipidemia, and postprandial hypertriglyceridemia"

ApoC-III is elevated in hypertriglyceridemia and contributes to TRL accumulation.

📊

Related Datasets

3

GTEx v8 Liver bulk RNA-seq gtex:GTEx_v8_Liver

Bulk RNA-seq reference tissue dataset from human liver, used to interpret hepatic lipid metabolism pathways central to hyperlipidemia (for example LDLR-PCSK9-APOB axis and triglyceride-rich lipoprotein handling).

human BULK RNA SEQ

liver tissue

Conditions: healthy tissue reference cohort

PMID:32913098

Dataset portal: https://gtexportal.org/home/datasets

Show evidence (1 reference)

PMID:32913098 SUPPORT Human Clinical

"Here, we present analyses of the version 8 data, examining 15,201 RNA-sequencing samples from 49 tissues of 838 postmortem donors."

Confirms GTEx v8 as a large cross-tissue RNA-seq resource that includes liver tissue relevant to lipid metabolism.

GTEx v8 Adipose (subcutaneous) bulk RNA-seq gtex:GTEx_v8_Adipose_Subcutaneous

Bulk RNA-seq dataset from subcutaneous adipose tissue, supporting analysis of adipose contributions to dyslipidemia, triglyceride metabolism, and insulin-resistance-associated lipid phenotypes.

human BULK RNA SEQ

adipose tissue

Conditions: healthy tissue reference cohort

PMID:32913098

Dataset portal: https://gtexportal.org/home/datasets

Show evidence (1 reference)

PMID:32913098 SUPPORT Human Clinical

"The Genotype-Tissue Expression (GTEx) project was established to characterize genetic effects on the transcriptome across human tissues and to link these regulatory mechanisms to trait and disease associations."

Supports use of adipose GTEx transcriptomes to connect gene regulation with lipid-related trait biology.

GTEx v8 Whole Blood bulk RNA-seq gtex:GTEx_v8_Whole_Blood

Bulk RNA-seq dataset from whole blood, useful for systemic inflammatory and immune-lipid signaling analyses in hyperlipidemia and cardiometabolic risk contexts.

human BULK RNA SEQ

whole blood

Conditions: healthy tissue reference cohort

PMID:32913098

Dataset portal: https://gtexportal.org/home/datasets

Show evidence (1 reference)

PMID:32913098 SUPPORT Human Clinical

"Leveraging the large diversity of tissues, we provide insights into the tissue specificity of genetic effects and show that cell type composition is a key factor in understanding gene regulatory mechanisms in human tissues."

Supports tissue-specific interpretation of blood transcriptomic signals relevant to lipid-associated complex traits.

🔬

Clinical Trials

4

NCT01764633 PHASE_III COMPLETED

FOURIER trial evaluating whether evolocumab added to statin therapy reduces major cardiovascular events in patients with clinically evident cardiovascular disease and elevated atherogenic risk.

Target Phenotypes: Increased LDL cholesterol concentration ↗ Coronary artery atherosclerosis ↗

Show evidence (1 reference)

clinicaltrials:NCT01764633 SUPPORT Human Clinical

"The primary objective was to evaluate the effect of treatment with evolocumab, compared with placebo, on the risk for cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in patients with clinically..."

Supports PCSK9 inhibition as a trial-validated approach for reducing cardiovascular risk in dyslipidemic high-risk populations.

NCT01663402 PHASE_III COMPLETED

ODYSSEY OUTCOMES trial evaluating alirocumab versus placebo after recent acute coronary syndrome in participants receiving evidence-based dyslipidemia management.

Target Phenotypes: Increased LDL cholesterol concentration ↗ Coronary artery atherosclerosis ↗

Show evidence (1 reference)

clinicaltrials:NCT01663402 SUPPORT Human Clinical

"To compare the effect of alirocumab with placebo on the occurrence of cardiovascular (CV) events (composite endpoint of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and non-fatal ischemic stroke, unstable angina (UA) requiring hospitalization) in participants..."

Supports clinical use of a PCSK9 monoclonal antibody in high-risk dyslipidemia with recent ACS.

NCT02993406 PHASE_III COMPLETED

CLEAR Outcomes trial assessing whether bempedoic acid lowers major cardiovascular events in statin-intolerant participants with or at high risk for cardiovascular disease.

Target Phenotypes: Increased LDL cholesterol concentration ↗ Coronary artery atherosclerosis ↗

Show evidence (1 reference)

clinicaltrials:NCT02993406 SUPPORT Human Clinical

"The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in participants who have or are at high risk for cardiovascular disease and are statin intolerant."

Supports bempedoic acid as an evidence-based option for LDL management in statin-intolerant populations.

NCT05355402 PHASE_II COMPLETED

Phase 2b trial of olezarsen in hypertriglyceridemia (including severe hypertriglyceridemia) assessing triglyceride lowering and broader apolipoprotein/lipoprotein changes.

Target Phenotypes: Hypertriglyceridemia ↗

Show evidence (1 reference)

clinicaltrials:NCT05355402 SUPPORT Human Clinical

"The purpose of the study was to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo at Months 6 and 12 and the proportion of participants who achieve different thresholds in fasting TG."

Supports ApoC-III antisense therapy development for severe triglyceride-driven hyperlipidemia.

{ }

Source YAML

click to show

name: Hyperlipidemia
creation_date: "2026-03-03T12:00:00Z"
updated_date: "2026-05-09T16:53:23Z"
description: >
  Hyperlipidemia is a heterogeneous dyslipidemia state characterized by elevated
  apoB-containing lipoproteins and/or triglyceride-rich lipoproteins. This entry
  focuses on common/polygenic and mixed hyperlipidemia mechanisms with shared
  downstream atherogenic consequences; monogenic familial hypercholesterolemia
  is curated separately.
category: Complex
disease_term:
  preferred_term: hyperlipidemia
  term:
    id: MONDO:0021187
    label: hyperlipidemia
parents:
- Metabolic Disease
- Cardiovascular Risk Factor
has_subtypes:
- name: Polygenic Hypercholesterolemia
  description: Common LDL-C-raising trait driven by the cumulative effect of multiple common variants plus dietary and metabolic modifiers, causing isolated hypercholesterolemia without a single high-penetrance Mendelian cause.
- name: Familial Combined Hyperlipidemia
  description: Common genetic lipid disorder characterized by elevated total cholesterol, LDL cholesterol, and/or triglycerides, with variable phenotypic expression among affected family members.
- name: Hypertriglyceridemia
  description: Elevation of triglyceride levels, which may be primary (genetic) or secondary to conditions such as obesity, diabetes, or alcohol use.
  evidence:
  - reference: DOI:10.3390/ijms25126364
    supports: SUPPORT
    snippet: The risk for coronary heart diseases varies from 57 to 76% in patients with hypertriglyceridemia.
    explanation: This review confirms the cardiovascular impact of hypertriglyceridemia.
    evidence_source: HUMAN_CLINICAL
- name: Mixed Hyperlipidemia
  description: Simultaneous elevation of both cholesterol and triglycerides, often associated with increased cardiovascular risk.
pathophysiology:
- name: Impaired Hepatic ApoB-Containing Lipoprotein Clearance
  description: >
    Reduced hepatic clearance of LDL and related apoB-containing lipoproteins due
    to partial LDLR-pathway insufficiency, increased PCSK9 activity, and other
    polygenic or metabolic perturbations. In this complex-trait context, the
    pathway is usually impaired by combined common-variant and environmental
    effects rather than a single receptor gene defect.
  genes:
  - preferred_term: LDLR
    term:
      id: hgnc:6547
      label: LDLR
  - preferred_term: APOB
    term:
      id: hgnc:603
      label: APOB
  - preferred_term: PCSK9
    term:
      id: hgnc:20001
      label: PCSK9
  cell_types:
  - preferred_term: Hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  biological_processes:
  - preferred_term: Receptor-mediated endocytosis
    term:
      id: GO:0006898
      label: receptor-mediated endocytosis
  - preferred_term: Cholesterol metabolic process
    term:
      id: GO:0008203
      label: cholesterol metabolic process
  downstream:
  - target: Oxidized LDL Infiltration of Arterial Intima
    description: Persistently elevated circulating LDL increases arterial wall exposure to atherogenic lipoproteins.
    evidence:
    - reference: PMID:30165986
      reference_title: "Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series."
      supports: SUPPORT
      snippet: Because atherogenic lipoproteins play a central causal role in the initiation and progression of atherosclerosis, maintaining optimal lipid levels is necessary to achieve ideal cardiovascular health.
      explanation: Increased LDL burden promotes initiation of arterial lipid-driven pathology.
      evidence_source: HUMAN_CLINICAL
  evidence:
  - reference: DOI:10.1038/s41467-024-46336-2
    supports: SUPPORT
    snippet: Proprotein convertase subtilisin/kexin type-9 (PCSK9) binds to and degrades low-density lipoprotein (LDL) receptor, leading to increase of LDL cholesterol in blood.
    explanation: Confirms that LDL receptor degradation by PCSK9 leads to impaired LDL clearance and elevated LDL-C levels.
    evidence_source: MODEL_ORGANISM
  - reference: PMID:28444290
    reference_title: "Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel."
    supports: SUPPORT
    snippet: Rare genetic mutations that cause reduced LDL receptor function lead to markedly higher LDL-C and a dose-dependent increase in the risk of ASCVD, whereas rare variants leading to lower LDL-C are associated with a correspondingly lower risk of ASCVD.
    explanation: Rare LDLR-pathway perturbations establish impaired hepatic LDL clearance as a core hypercholesterolemic mechanism that also informs common LDL-C elevation.
    evidence_source: HUMAN_CLINICAL
- name: PCSK9-Mediated LDL Receptor Degradation
  description: >
    PCSK9 binds to LDL receptors on the hepatocyte surface and promotes their
    lysosomal degradation, reducing receptor recycling and the number of
    receptors available for LDL clearance. Increased PCSK9 activity, whether
    genetically determined or acquired, can raise LDL-C. PCSK9 also directly
    induces inflammation independently of the LDL receptor via CAP1-mediated
    NF-kB signaling.
  genes:
  - preferred_term: PCSK9
    term:
      id: hgnc:20001
      label: PCSK9
  cell_types:
  - preferred_term: Hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: Endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: Receptor-mediated endocytosis
    term:
      id: GO:0006898
      label: receptor-mediated endocytosis
  - preferred_term: Inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: Impaired Hepatic ApoB-Containing Lipoprotein Clearance
    description: PCSK9-driven LDLR degradation lowers receptor availability and impairs LDL clearance.
    evidence:
    - reference: DOI:10.1038/s41467-024-46336-2
      supports: SUPPORT
      snippet: Proprotein convertase subtilisin/kexin type-9 (PCSK9) binds to and degrades low-density lipoprotein (LDL) receptor, leading to increase of LDL cholesterol in blood.
      explanation: Directly links PCSK9 activity to LDL receptor loss and impaired clearance.
      evidence_source: MODEL_ORGANISM
  evidence:
  - reference: DOI:10.1038/s41467-024-46336-2
    supports: SUPPORT
    snippet: PCSK9 itself directly induces inflammation and aggravates atherosclerosis independently of the LDL receptor.
    explanation: Demonstrates that PCSK9 has LDLR-independent pro-inflammatory functions, contributing to atherosclerosis beyond its role in LDL receptor degradation.
    evidence_source: MODEL_ORGANISM
  - reference: DOI:10.1038/s41467-024-46336-2
    supports: SUPPORT
    snippet: Adenylyl cyclase-associated protein 1 (CAP1) is the main binding partner of PCSK9 and indispensable for the inflammatory action of PCSK9, including induction of cytokines, Toll like receptor 4, and scavenger receptors, enhancing the uptake of oxidized LDL.
    explanation: Identifies the CAP1-mediated signaling pathway through which PCSK9 promotes inflammation and foam cell formation.
    evidence_source: MODEL_ORGANISM
- name: Dysregulated Hepatic Lipogenesis and VLDL Overproduction
  description: >
    Increased de novo lipogenesis in the liver driven by insulin resistance and
    transcription factor SREBP-1c activation leads to overproduction of VLDL particles,
    contributing to elevated triglycerides and small dense LDL. VLDL assembly depends
    on apoB lipidation by microsomal triglyceride transfer protein (MTP) in the
    rough endoplasmic reticulum.
  cell_types:
  - preferred_term: Hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  biological_processes:
  - preferred_term: Lipid biosynthetic process
    term:
      id: GO:0008610
      label: lipid biosynthetic process
  - preferred_term: Lipid metabolic process
    term:
      id: GO:0006629
      label: lipid metabolic process
  downstream:
  - target: Impaired Lipoprotein Lipase Activity and ApoC-III Dysregulation
    description: Increased VLDL output increases dependence on LPL-mediated triglyceride-rich lipoprotein processing.
    evidence:
    - reference: DOI:10.1186/s12944-023-01993-y
      supports: PARTIAL
      snippet: Preclinical investigations have revealed that interventions targeting VLDL production or promoting VLDL metabolism, independent of the LDL receptor, can potentially decrease cholesterol levels and provide therapeutic benefits.
      explanation: Supports a mechanistic coupling between VLDL metabolism and downstream lipoprotein-processing pathways.
      evidence_source: OTHER
  evidence:
  - reference: DOI:10.1186/s12944-023-01993-y
    supports: SUPPORT
    snippet: Preclinical investigations have revealed that interventions targeting VLDL production or promoting VLDL metabolism, independent of the LDL receptor, can potentially decrease cholesterol levels and provide therapeutic benefits.
    explanation: Confirms that VLDL production is a key therapeutic target in hyperlipidemia and that VLDL overproduction contributes to elevated cholesterol levels.
    evidence_source: OTHER
- name: Impaired Lipoprotein Lipase Activity and ApoC-III Dysregulation
  description: >
    Deficiency or dysfunction of lipoprotein lipase (LPL) impairs hydrolysis of
    triglyceride-rich lipoproteins (chylomicrons and VLDL) in capillary endothelium,
    resulting in severe hypertriglyceridemia. Apolipoprotein C-III (ApoC-III) is a
    key inhibitor of LPL and also reduces hepatic uptake of triglyceride-rich
    lipoprotein remnants, contributing to hypertriglyceridemia and cardiovascular risk.
  genes:
  - preferred_term: LPL
    term:
      id: hgnc:6677
      label: LPL
  - preferred_term: APOC3
    term:
      id: hgnc:610
      label: APOC3
  biological_processes:
  - preferred_term: Lipid metabolic process
    term:
      id: GO:0006629
      label: lipid metabolic process
  downstream:
  - target: Oxidized LDL Infiltration of Arterial Intima
    description: Persistent accumulation of triglyceride-rich remnants contributes to atherogenic lipoprotein burden in arterial walls.
    evidence:
    - reference: PMID:30165986
      reference_title: "Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series."
      supports: PARTIAL
      snippet: Because atherogenic lipoproteins play a central causal role in the initiation and progression of atherosclerosis, maintaining optimal lipid levels is necessary to achieve ideal cardiovascular health.
      explanation: Supports contribution of atherogenic lipoprotein excess to arterial disease initiation and progression.
      evidence_source: HUMAN_CLINICAL
  evidence:
  - reference: DOI:10.1007/s11883-023-01080-8
    supports: SUPPORT
    snippet: ApoC-III has been recently considered an important player in insulin resistance mechanisms, lipodystrophy, diabetic dyslipidemia, and postprandial hypertriglyceridemia
    explanation: Confirms the central role of ApoC-III in triglyceride metabolism dysregulation and its broader cardiometabolic effects.
    evidence_source: HUMAN_CLINICAL
  - reference: DOI:10.1007/s11883-023-01080-8
    supports: SUPPORT
    snippet: the inhibition of ApoC-III is a promising therapeutical strategy for the management of severe hypertriglyceridemia and in CVD prevention
    explanation: Validates ApoC-III as a key pathogenic molecule in hypertriglyceridemia.
    evidence_source: HUMAN_CLINICAL
- name: Oxidized LDL Infiltration of Arterial Intima
  description: >
    Oxidized LDL infiltrates and accumulates in the arterial intima, establishing the
    initiating lipid milieu for atherogenesis.
  cell_types:
  - preferred_term: Endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: Inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: Macrophage Recruitment to Arterial Intima
    description: Intimal oxidized LDL promotes leukocyte attraction and macrophage influx.
    evidence:
    - reference: PMID:30165986
      reference_title: "Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series."
      supports: SUPPORT
      snippet: Because atherogenic lipoproteins play a central causal role in the initiation and progression of atherosclerosis, maintaining optimal lipid levels is necessary to achieve ideal cardiovascular health.
      explanation: Supports atherogenic lipoprotein-driven initiation of arterial inflammatory cascades.
      evidence_source: HUMAN_CLINICAL
  evidence:
  - reference: PMID:30165986
    reference_title: "Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series."
    supports: SUPPORT
    snippet: Because atherogenic lipoproteins play a central causal role in the initiation and progression of atherosclerosis, maintaining optimal lipid levels is necessary to achieve ideal cardiovascular health.
    explanation: Supports oxLDL-associated lipoprotein burden as an initiating event in atherosclerosis.
    evidence_source: HUMAN_CLINICAL
- name: Macrophage Recruitment to Arterial Intima
  description: >
    Inflammatory signaling within lipid-rich intima recruits macrophages to arterial lesions.
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: Endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: Inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: Macrophage-Derived Foam Cell Formation
    description: Recruited macrophages internalize oxidized lipoproteins and transition toward foam cells.
    evidence:
    - reference: DOI:10.1038/s41467-024-46336-2
      supports: SUPPORT
      snippet: Adenylyl cyclase-associated protein 1 (CAP1) is the main binding partner of PCSK9 and indispensable for the inflammatory action of PCSK9, including induction of cytokines, Toll like receptor 4, and scavenger receptors, enhancing the uptake of oxidized LDL.
      explanation: Supports inflammatory signaling and enhanced oxidized-LDL uptake driving macrophage transition.
      evidence_source: MODEL_ORGANISM
  evidence:
  - reference: DOI:10.3390/nu16132156
    supports: SUPPORT
    snippet: Disruption in any of these steps results in pathophysiological abnormalities such as dyslipidemia, obesity, insulin resistance, inflammation, atherosclerosis, peripheral artery disease, and cardiovascular diseases.
    explanation: Supports inflammation-coupled transition from lipid imbalance to arterial immune-cell pathology.
    evidence_source: HUMAN_CLINICAL
- name: Macrophage-Derived Foam Cell Formation
  description: >
    Macrophages in lipid-rich intima accumulate oxidized lipoproteins and differentiate
    into foam cells.
  cell_types:
  - preferred_term: Macrophage-derived foam cell
    term:
      id: CL:0000517
      label: macrophage derived foam cell
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: Macrophage-derived foam cell differentiation
    term:
      id: GO:0010742
      label: macrophage derived foam cell differentiation
  downstream:
  - target: Atherosclerotic Plaque Development
    description: Foam-cell accumulation drives fatty-streak maturation and plaque development.
    evidence:
    - reference: PMID:28444290
      reference_title: "Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel."
      supports: SUPPORT
      snippet: Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.
      explanation: Supports LDL-driven downstream progression to clinical atherosclerotic disease.
      evidence_source: HUMAN_CLINICAL
  evidence:
  - reference: DOI:10.1038/s41467-024-46336-2
    supports: SUPPORT
    snippet: Adenylyl cyclase-associated protein 1 (CAP1) is the main binding partner of PCSK9 and indispensable for the inflammatory action of PCSK9, including induction of cytokines, Toll like receptor 4, and scavenger receptors, enhancing the uptake of oxidized LDL.
    explanation: Supports enhanced oxidized-LDL uptake as a proximate mechanism for foam cell formation.
    evidence_source: MODEL_ORGANISM
- name: Atherosclerotic Plaque Development
  description: >
    Chronic intimal lipid retention and inflammation result in atherosclerotic plaque
    formation as a major end-organ consequence of sustained hyperlipidemia.
  cell_types:
  - preferred_term: Endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  - preferred_term: Vascular smooth muscle cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  biological_processes:
  - preferred_term: Inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: DOI:10.3390/nu16132156
    supports: SUPPORT
    snippet: Disruption in any of these steps results in pathophysiological abnormalities such as dyslipidemia, obesity, insulin resistance, inflammation, atherosclerosis, peripheral artery disease, and cardiovascular diseases.
    explanation: Confirms the pathological link between lipoprotein dysregulation and atherosclerosis.
    evidence_source: HUMAN_CLINICAL
  - reference: PMID:28444290
    reference_title: "Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel."
    supports: SUPPORT
    snippet: Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.
    explanation: The definitive EAS consensus statement establishing LDL as a causal factor in atherosclerotic cardiovascular disease.
    evidence_source: HUMAN_CLINICAL
phenotypes:
- category: CARDIOVASCULAR
  name: Elevated Triglycerides
  description: Elevated serum triglyceride levels, associated with increased cardiovascular risk and risk of pancreatitis at very high levels.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Hypertriglyceridemia
    term:
      id: HP:0002155
      label: Hypertriglyceridemia
  evidence:
  - reference: DOI:10.3390/ijms25126364
    supports: SUPPORT
    snippet: the higher the plasma concentrations in TGs, the higher the incidence and prevalence of death, myocardial infarction, and stroke.
    explanation: Confirms the dose-dependent relationship between elevated triglycerides and adverse cardiovascular outcomes.
    evidence_source: HUMAN_CLINICAL
- category: CARDIOVASCULAR
  name: Premature Atherosclerosis
  description: Early onset of atherosclerotic disease, particularly in familial forms of hyperlipidemia.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Premature atherosclerosis
    term:
      id: HP:0004416
      label: Precocious atherosclerosis
  evidence:
  - reference: PMID:28444290
    reference_title: "Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel."
    supports: SUPPORT
    snippet: any mechanism of lowering plasma LDL particle concentration should reduce the risk of ASCVD events proportional to the absolute reduction in LDL-C and the cumulative duration of exposure to lower LDL-C
    explanation: Establishes that cumulative LDL exposure drives atherosclerosis, explaining why familial hyperlipidemia with lifelong elevation causes premature disease.
    evidence_source: HUMAN_CLINICAL
- category: DERMATOLOGIC
  name: Xanthomas
  description: Lipid deposits in the skin and tendons, particularly tendon xanthomas in familial hypercholesterolemia and eruptive xanthomas in severe hypertriglyceridemia.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Xanthomatosis
    term:
      id: HP:0000991
      label: Xanthomatosis
- category: OPHTHALMOLOGIC
  name: Corneal Arcus
  description: A white or grey opaque ring in the corneal margin caused by lipid deposition, common in older individuals but indicative of hyperlipidemia when present in younger patients.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Corneal arcus
    term:
      id: HP:0001084
      label: Corneal arcus
- category: CARDIOVASCULAR
  name: Coronary Artery Disease
  description: Atherosclerotic narrowing of coronary arteries leading to angina, myocardial infarction, and sudden cardiac death.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Coronary artery atherosclerosis
    term:
      id: HP:0001677
      label: Coronary artery atherosclerosis
  evidence:
  - reference: DOI:10.3390/ijms25126364
    supports: SUPPORT
    snippet: The risk for coronary heart diseases varies from 57 to 76% in patients with hypertriglyceridemia.
    explanation: Quantifies the high coronary heart disease risk in patients with hyperlipidemia.
    evidence_source: HUMAN_CLINICAL
- category: CARDIOVASCULAR
  name: Decreased HDL Cholesterol
  description: Low HDL cholesterol levels, often accompanying elevated triglycerides and associated with increased cardiovascular risk.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Decreased HDL cholesterol concentration
    term:
      id: HP:0003233
      label: Decreased HDL cholesterol concentration
- category: CARDIOVASCULAR
  name: Increased LDL Cholesterol
  description: Elevated LDL cholesterol concentration, the primary lipid abnormality driving atherosclerotic cardiovascular disease.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Increased LDL cholesterol concentration
    term:
      id: HP:0003141
      label: Increased LDL cholesterol concentration
  evidence:
  - reference: PMID:28444290
    reference_title: "Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel."
    supports: SUPPORT
    snippet: Separate meta-analyses of over 200 prospective cohort studies, Mendelian randomization studies, and randomized trials including more than 2 million participants with over 20 million person-years of follow-up and over 150 000 cardiovascular events demonstrate a remarkably consistent dose-dependent log-linear association between the absolute magnitude of exposure of the vasculature to LDL-C and the risk of ASCVD
    explanation: Establishes the dose-dependent association between LDL-C exposure and ASCVD risk.
    evidence_source: HUMAN_CLINICAL
  - reference: DOI:10.5114/aoms/174743
    supports: SUPPORT
    snippet: almost 4 million deaths per year are attributed to LDL-C
    explanation: Demonstrates the massive global burden attributable to elevated LDL cholesterol.
    evidence_source: HUMAN_CLINICAL
biochemical:
- name: Total Cholesterol
  presence: Elevated
  context: Elevated circulating cholesterol burden, typically reflecting increased apoB-containing lipoproteins in common hyperlipidemia phenotypes.
  frequency: FREQUENT
  specificity: Moderate; should be interpreted with LDL-C, triglycerides, and HDL-C for subtype resolution.
  biomarker_term:
    preferred_term: cholesterol
    term:
      id: NCIT:C369
      label: Cholesterol
  evidence:
  - reference: DOI:10.3390/nu16132156
    supports: SUPPORT
    snippet: Disruption in any of these steps results in pathophysiological abnormalities such as dyslipidemia, obesity, insulin resistance, inflammation, atherosclerosis, peripheral artery disease, and cardiovascular diseases.
    explanation: Dyslipidemia, including elevated total cholesterol, is a primary manifestation of lipoprotein metabolism disruption.
    evidence_source: HUMAN_CLINICAL
- name: LDL Cholesterol
  presence: Elevated
  context: Core atherogenic lipid abnormality driving atherosclerotic cardiovascular risk in both monogenic and polygenic hyperlipidemia.
  frequency: VERY_FREQUENT
  specificity: High for atherogenic risk stratification and treatment targeting.
  biomarker_term:
    preferred_term: low-density lipoprotein cholesterol measurement
    term:
      id: NCIT:C105588
      label: Low Density Lipoprotein Cholesterol Measurement
  evidence:
  - reference: PMID:28444290
    reference_title: "Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel."
    supports: SUPPORT
    snippet: Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.
    explanation: Elevated LDL cholesterol is the central biochemical abnormality in hyperlipidemia and causally linked to ASCVD.
    evidence_source: HUMAN_CLINICAL
- name: Triglycerides
  presence: Elevated
  context: Elevated triglyceride-rich lipoproteins are common in mixed and insulin-resistant dyslipidemia and increase cardiometabolic risk.
  frequency: FREQUENT
  specificity: Moderate; severe elevations indicate heightened pancreatitis risk and distinct therapeutic priorities.
  evidence:
  - reference: DOI:10.3390/ijms25126364
    supports: SUPPORT
    snippet: the higher the plasma concentrations in TGs, the higher the incidence and prevalence of death, myocardial infarction, and stroke.
    explanation: Confirms triglyceride elevation as a key biochemical feature associated with cardiovascular outcomes.
    evidence_source: HUMAN_CLINICAL
  - reference: PMID:30021845
    reference_title: "Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease Incidence."
    supports: SUPPORT
    snippet: Atherogenic dyslipidemia characterized by increased small LDL particle (LDL-P) concentration, rather than total LDL cholesterol content, along with elevated triglyceride-rich lipoproteins and low high-density lipoprotein (HDL) cholesterol (HDL-C), may be the primary lipid driver of PAD risk.
    explanation: Supports triglyceride-rich lipoprotein elevation as a central component of atherogenic dyslipidemia.
    evidence_source: HUMAN_CLINICAL
- name: HDL Cholesterol
  presence: Decreased
  context: Reduced HDL-C commonly co-occurs with elevated triglyceride-rich lipoproteins in atherogenic dyslipidemia.
  frequency: FREQUENT
  specificity: Low in isolation; most informative when interpreted with triglycerides, LDL-related markers, and TC:HDL-C ratio.
  biomarker_term:
    preferred_term: high-density lipoprotein cholesterol measurement
    term:
      id: NCIT:C105587
      label: High Density Lipoprotein Cholesterol Measurement
  evidence:
  - reference: PMID:30021845
    reference_title: "Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease Incidence."
    supports: SUPPORT
    snippet: Other features of atherogenic dyslipidemia, including elevations in TC:HDL-C, elevations in triglyceride-rich lipoproteins, and low standard and nuclear magnetic resonance-derived measures of HDL, were significant risk determinants.
    explanation: Directly supports reduced HDL as part of the clinically relevant atherogenic dyslipidemia signature.
    evidence_source: HUMAN_CLINICAL
  - reference: PMID:40489011
    reference_title: "High Density Lipoprotein Particle Composition, Functionality, Deficiency, and Atherosclerotic Cardiovascular Disease Risk: A Review."
    supports: SUPPORT
    snippet: Decreased serum high-density-lipoprotein-cholesterol (HDL-C), HDL particles, and cell-cholesterol-efflux-capacity have all been associated with increased atherosclerotic cardiovascular disease (ASCVD) risk.
    explanation: Summarizes independent HDL-related associations with ASCVD risk.
    evidence_source: OTHER
- name: TC:HDL-C Ratio
  presence: Elevated
  context: Composite atherogenic index integrating cholesterol burden and relative HDL deficiency.
  frequency: FREQUENT
  specificity: High for vascular risk enrichment in atherogenic dyslipidemia profiles.
  evidence:
  - reference: PMID:30021845
    reference_title: "Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease Incidence."
    supports: SUPPORT
    snippet: In age-adjusted analyses, while LDL cholesterol was not associated with incident PAD, we found significant associations for increased total and small LDL-P concentrations, triglycerides, and concentrations of very LDL (VLDL) particle (VLDL-P) subclasses, increased total cholesterol (TC):HDL-C, low HDL-C, and low HDL particle (HDL-P) concentration (all P for extreme tertile comparisons <0.05).
    explanation: Provides quantitative cohort evidence that elevated TC:HDL-C tracks higher vascular event risk.
    evidence_source: HUMAN_CLINICAL
- name: Apolipoprotein C-III
  presence: Elevated
  context: hypertriglyceridemia
  frequency: FREQUENT
  specificity: Moderate for triglyceride-rich lipoprotein dysregulation.
  biomarker_term:
    preferred_term: apolipoprotein C-III
    term:
      id: NCIT:C117099
      label: Apolipoprotein C-III
  evidence:
  - reference: DOI:10.1007/s11883-023-01080-8
    supports: SUPPORT
    snippet: ApoC-III has been recently considered an important player in insulin resistance mechanisms, lipodystrophy, diabetic dyslipidemia, and postprandial hypertriglyceridemia
    explanation: ApoC-III is elevated in hypertriglyceridemia and contributes to TRL accumulation.
    evidence_source: HUMAN_CLINICAL
genetic:
- name: LDLR
  gene_term:
    preferred_term: LDLR
    term:
      id: hgnc:6547
      label: LDLR
  association: Monogenic Cause in Familial Hypercholesterolemia; Core LDL-C Clearance Pathway
  inheritance:
  - name: Autosomal Dominant
  notes: Rare loss-of-function variants cause familial hypercholesterolemia, while broader variation in LDLR-pathway activity contributes to hypercholesterolemic phenotypes through reduced hepatic LDL clearance.
  evidence:
  - reference: PMID:28444290
    reference_title: "Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel."
    supports: SUPPORT
    snippet: Rare genetic mutations that cause reduced LDL receptor function lead to markedly higher LDL-C and a dose-dependent increase in the risk of ASCVD
    explanation: Confirms that LDLR loss-of-function is sufficient to raise LDL-C and ASCVD risk, establishing the pathway as mechanistically central to hypercholesterolemia.
    evidence_source: HUMAN_CLINICAL
- name: PCSK9
  gene_term:
    preferred_term: PCSK9
    term:
      id: hgnc:20001
      label: PCSK9
  association: Monogenic Cause in Familial Hypercholesterolemia and Modifier of LDL-C Burden
  inheritance:
  - name: Autosomal Dominant
  notes: Gain-of-function variants cause monogenic hypercholesterolemia, and higher PCSK9 activity also contributes to common LDL-C elevation and vascular inflammation.
  evidence:
  - reference: DOI:10.1038/s41467-024-46336-2
    supports: SUPPORT
    snippet: Proprotein convertase subtilisin/kexin type-9 (PCSK9) binds to and degrades low-density lipoprotein (LDL) receptor, leading to increase of LDL cholesterol in blood.
    explanation: Confirms the canonical mechanism of PCSK9-mediated LDL receptor degradation.
    evidence_source: MODEL_ORGANISM
- name: APOB
  gene_term:
    preferred_term: APOB
    term:
      id: hgnc:603
      label: APOB
  association: Monogenic Cause and ApoB-Trafficking Determinant
  inheritance:
  - name: Autosomal Dominant
  notes: Rare APOB variants cause familial defective apolipoprotein B, while apoB availability more generally shapes VLDL and LDL production in mixed dyslipidemia.
  evidence:
  - reference: PMID:22417841
    reference_title: "Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients."
    supports: SUPPORT
    snippet: Autosomal dominant hypercholesterolemia (ADH) is commonly caused by mutations in the low-density lipoprotein (LDL) receptor gene (LDLR), in the apolipoprotein B-100 gene (APOB), or in the proprotein convertase subtilisin kexine 9 gene (PCSK9).
    explanation: Directly supports APOB as a canonical LDL-pathway gene whose perturbation can produce hypercholesterolemia.
    evidence_source: HUMAN_CLINICAL
- name: LPL
  gene_term:
    preferred_term: LPL
    term:
      id: hgnc:6677
      label: LPL
  association: Monogenic Cause in Severe Hypertriglyceridemia
  inheritance:
  - name: Autosomal Recessive
  notes: Loss-of-function mutations cause familial chylomicronemia syndrome with severe hypertriglyceridemia.
- name: APOE
  gene_term:
    preferred_term: APOE
    term:
      id: hgnc:613
      label: APOE
  association: Lipoprotein Clearance Modifier
  notes: The APOE e4 allele is associated with increased LDL cholesterol, while APOE e2 can cause type III hyperlipoproteinemia.
- name: APOC3
  gene_term:
    preferred_term: APOC3
    term:
      id: hgnc:610
      label: APOC3
  association: Triglyceride-Rich Lipoprotein Modifier
  notes: Elevated ApoC-III inhibits lipoprotein lipase and reduces hepatic uptake of triglyceride-rich lipoprotein remnants, contributing to hypertriglyceridemia.
  evidence:
  - reference: DOI:10.1007/s11883-023-01080-8
    supports: SUPPORT
    snippet: ApoC-III is clearly linked to cardiovascular disease (CVD) risk, and progression of coronary artery disease (CAD) as well as the calcification of aortic valve
    explanation: Confirms the pathogenic role of APOC3 in cardiovascular disease.
    evidence_source: HUMAN_CLINICAL
environmental:
- name: High Saturated Fat Diet
  description: Dietary intake of saturated and trans fats increases hepatic cholesterol synthesis and reduces LDL receptor expression, raising serum LDL cholesterol.
  evidence:
  - reference: PMID:28166253
    reference_title: "Effects of a very high saturated fat diet on LDL particles in adults with atherogenic dyslipidemia: A randomized controlled trial."
    supports: SUPPORT
    snippet: Previous studies have shown that increases in LDL-cholesterol resulting from substitution of dietary saturated fat for carbohydrate or unsaturated fat are due primarily to increases in large cholesterol-enriched LDL, with minimal changes in small, dense LDL particles and apolipoprotein B.
    explanation: Directly supports saturated-fat-driven LDL-C elevation.
    evidence_source: HUMAN_CLINICAL
  - reference: PMID:37979064
    reference_title: "Obesity and Dyslipidemia."
    supports: SUPPORT
    snippet: Composition of nutrients, esp. fatty acids, influences lipid levels.
    explanation: Supports nutrient composition, including fatty acids, as a modifiable driver of lipid abnormalities.
    evidence_source: OTHER
- name: Sedentary Lifestyle
  description: Physical inactivity is associated with reduced HDL cholesterol, elevated triglycerides, and impaired lipid metabolism.
  evidence:
  - reference: PMID:28748993
    reference_title: "[Sedentary lifestyle is associated with metabolic and cardiovascular risk factors independent of physical activity]."
    supports: SUPPORT
    snippet: Per one hour increase in sedentary behavior there were significant adverse changes in glucose (4.79 mg/dl), insulin (2.73 pmol/l), HOMA-IR (0.75), BMI (0.69 kg/m²), waist circumference (1.95 cm), fat mass (1.03%), total cholesterol (9.73 mg/dl), HDL-cholesterol (-3.50 mg/dl), LDL-cholesterol (10.7 mg/dl) and triglycerides (12.4 mg/dl).
    explanation: Quantifies adverse lipid changes (lower HDL and higher LDL/triglycerides) with increasing sedentary time.
    evidence_source: HUMAN_CLINICAL
  - reference: PMID:28748993
    reference_title: "[Sedentary lifestyle is associated with metabolic and cardiovascular risk factors independent of physical activity]."
    supports: SUPPORT
    snippet: The detrimental effect of sedentary behaviors on cardiometabolic and obesity-related traits is independent of physical activity levels.
    explanation: Supports sedentary behavior as an independent environmental risk factor, not only the absence of exercise.
    evidence_source: HUMAN_CLINICAL
- name: Obesity
  description: Excess adiposity promotes insulin resistance, hepatic VLDL overproduction, and dyslipidemia characterized by elevated triglycerides and low HDL.
  evidence:
  - reference: DOI:10.3390/nu16132156
    supports: SUPPORT
    snippet: Disruption in any of these steps results in pathophysiological abnormalities such as dyslipidemia, obesity, insulin resistance, inflammation, atherosclerosis, peripheral artery disease, and cardiovascular diseases.
    explanation: Links obesity to dyslipidemia and insulin resistance as interconnected metabolic abnormalities.
    evidence_source: HUMAN_CLINICAL
  - reference: PMID:20563664
    reference_title: "Association of body mass index and lipid profiles: evaluation of a broad spectrum of body mass index patients including the morbidly obese."
    supports: SUPPORT
    snippet: Higher BMI was inversely associated with HDL and directly associated with TG.
    explanation: Direct human clinical evidence linking obesity severity to the characteristic high-TG/low-HDL dyslipidemia pattern.
    evidence_source: HUMAN_CLINICAL
  - reference: PMID:37979064
    reference_title: "Obesity and Dyslipidemia."
    supports: SUPPORT
    snippet: Weight loss either with diet or antiobestic medication induces the decrease in triglycerides (TG) and LDL-C and the increase in HDL-C.
    explanation: Supports a causal obesity-lipid relationship by showing lipid improvements following weight reduction.
    evidence_source: OTHER
treatments:
- name: Statin Therapy
  description: HMG-CoA reductase inhibitors that reduce hepatic cholesterol synthesis and upregulate LDL receptor expression, lowering LDL cholesterol by 30-50%.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: statin
      term:
        id: CHEBI:87631
        label: statin
  evidence:
  - reference: DOI:10.3390/nu16132156
    supports: SUPPORT
    snippet: Several medications are available for the treatment of dyslipoproteinemia. These include statins, fibrates, ezetimibe, niacin, PCSK9 inhibitors, evinacumab
    explanation: Lists statins as first-line pharmacotherapy for dyslipoproteinemia.
    evidence_source: HUMAN_CLINICAL
  - reference: DOI:10.5114/aoms/174743
    supports: SUPPORT
    snippet: In 2023 there are still even 75% of patients over the LDL-C target, and hypercholesterolemia is the most common and the worst monitored CVD risk factor.
    explanation: Highlights the ongoing need for effective statin therapy given high rates of uncontrolled LDL-C.
    evidence_source: HUMAN_CLINICAL
- name: PCSK9 Inhibitors
  description: Monoclonal antibodies (evolocumab, alirocumab) that block PCSK9 and increase hepatic LDL receptor recycling, producing potent LDL lowering.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: PCSK9 inhibitor
      term:
        id: NCIT:C190797
        label: PCSK9 Inhibitor
    - preferred_term: alirocumab
      term:
        id: NCIT:C174849
        label: Alirocumab
    - preferred_term: evolocumab
      term:
        id: NCIT:C174672
        label: Evolocumab
- name: Ezetimibe
  description: Inhibits intestinal cholesterol absorption at the brush border via the NPC1L1 transporter, reducing LDL cholesterol when used alone or in combination with statins.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: ezetimibe
      term:
        id: NCIT:C47529
        label: Ezetimibe
- name: Fibrates
  description: PPARalpha agonists that reduce triglyceride levels by enhancing fatty acid oxidation and lipoprotein lipase activity.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: fenofibrate
      term:
        id: NCIT:C29047
        label: Fenofibrate
    - preferred_term: gemfibrozil
      term:
        id: NCIT:C29071
        label: Gemfibrozil
- name: Lifestyle Modification
  description: Dietary changes (reduced saturated fat, increased fiber), regular exercise, weight management, and smoking cessation as first-line interventions.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
- name: Omega-3 Fatty Acids
  description: High-dose EPA/DHA preparations reduce triglycerides by decreasing hepatic VLDL production.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: omega-3 fatty acid
      term:
        id: CHEBI:25681
        label: omega-3 fatty acid
    - preferred_term: icosapentaenoic acid
      term:
        id: CHEBI:36006
        label: icosapentaenoic acid
- name: Bempedoic Acid
  description: ATP citrate lyase inhibitor that reduces cholesterol biosynthesis upstream of HMG-CoA reductase, used in statin-intolerant patients.
  treatment_term:
    preferred_term: targeted therapy
    term:
      id: NCIT:C93352
      label: Targeted Therapy
    therapeutic_agent:
    - preferred_term: bempedoic acid
      term:
        id: CHEBI:149601
        label: bempedoic acid
- name: ApoC-III Inhibitors
  description: Antisense oligonucleotides such as olezarsen that reduce apolipoprotein C-III levels, significantly lowering triglycerides in patients with hypertriglyceridemia.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: antisense oligonucleotides
      term:
        id: NCIT:C1291
        label: Antisense Oligonucleotides
    - preferred_term: olezarsen
      term:
        id: NCIT:C180652
        label: Olezarsen
  evidence:
  - reference: DOI:10.1186/s12944-024-02297-5
    supports: SUPPORT
    snippet: Olezarsen is a GalNAc3-conjugated, hepatic-targeted antisense oligonucleotide that lowers apolipoprotein C-III (apoC-III) and triglyceride levels.
    explanation: Describes the mechanism and clinical efficacy of the ApoC-III targeting antisense approach.
    evidence_source: HUMAN_CLINICAL
  - reference: DOI:10.1186/s12944-024-02297-5
    supports: SUPPORT
    snippet: In the MD cohort, at Day 92 the percentage reduction in apoC-III/TG was − 81.6/ − 73.8% vs − 17.2/ − 40.8% reduction in placebo.
    explanation: Demonstrates substantial triglyceride reduction achieved with ApoC-III inhibition in clinical trials.
    evidence_source: HUMAN_CLINICAL
datasets:
- accession: gtex:GTEx_v8_Liver
  title: GTEx v8 Liver bulk RNA-seq
  description: >
    Bulk RNA-seq reference tissue dataset from human liver, used to interpret
    hepatic lipid metabolism pathways central to hyperlipidemia (for example
    LDLR-PCSK9-APOB axis and triglyceride-rich lipoprotein handling).
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_types:
  - preferred_term: liver tissue
    tissue_term:
      preferred_term: liver
      term:
        id: UBERON:0002107
        label: liver
  conditions:
  - healthy tissue reference cohort
  publication: PMID:32913098
  evidence:
  - reference: PMID:32913098
    reference_title: "The GTEx Consortium atlas of genetic regulatory effects across human tissues."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Here, we present analyses of the version 8 data, examining 15,201 RNA-sequencing samples from 49 tissues of 838 postmortem donors.
    explanation: Confirms GTEx v8 as a large cross-tissue RNA-seq resource that includes liver tissue relevant to lipid metabolism.
  notes: "Dataset portal: https://gtexportal.org/home/datasets"
- accession: gtex:GTEx_v8_Adipose_Subcutaneous
  title: GTEx v8 Adipose (subcutaneous) bulk RNA-seq
  description: >
    Bulk RNA-seq dataset from subcutaneous adipose tissue, supporting analysis
    of adipose contributions to dyslipidemia, triglyceride metabolism, and
    insulin-resistance-associated lipid phenotypes.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_types:
  - preferred_term: adipose tissue
    tissue_term:
      preferred_term: adipose tissue
      term:
        id: UBERON:0001013
        label: adipose tissue
  conditions:
  - healthy tissue reference cohort
  publication: PMID:32913098
  evidence:
  - reference: PMID:32913098
    reference_title: "The GTEx Consortium atlas of genetic regulatory effects across human tissues."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The Genotype-Tissue Expression (GTEx) project was established to characterize genetic effects on the transcriptome across human tissues and to link these regulatory mechanisms to trait and disease associations.
    explanation: Supports use of adipose GTEx transcriptomes to connect gene regulation with lipid-related trait biology.
  notes: "Dataset portal: https://gtexportal.org/home/datasets"
- accession: gtex:GTEx_v8_Whole_Blood
  title: GTEx v8 Whole Blood bulk RNA-seq
  description: >
    Bulk RNA-seq dataset from whole blood, useful for systemic inflammatory and
    immune-lipid signaling analyses in hyperlipidemia and cardiometabolic risk
    contexts.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_types:
  - preferred_term: whole blood
    tissue_term:
      preferred_term: blood
      term:
        id: UBERON:0000178
        label: blood
  conditions:
  - healthy tissue reference cohort
  publication: PMID:32913098
  evidence:
  - reference: PMID:32913098
    reference_title: "The GTEx Consortium atlas of genetic regulatory effects across human tissues."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Leveraging the large diversity of tissues, we provide insights into the tissue specificity of genetic effects and show that cell type composition is a key factor in understanding gene regulatory mechanisms in human tissues.
    explanation: Supports tissue-specific interpretation of blood transcriptomic signals relevant to lipid-associated complex traits.
  notes: "Dataset portal: https://gtexportal.org/home/datasets"
clinical_trials:
- name: NCT01764633
  phase: PHASE_III
  status: COMPLETED
  description: >
    FOURIER trial evaluating whether evolocumab added to statin therapy reduces
    major cardiovascular events in patients with clinically evident cardiovascular
    disease and elevated atherogenic risk.
  target_phenotypes:
  - preferred_term: Increased LDL cholesterol concentration
    term:
      id: HP:0003141
      label: Increased LDL cholesterol concentration
  - preferred_term: Coronary artery atherosclerosis
    term:
      id: HP:0001677
      label: Coronary artery atherosclerosis
  evidence:
  - reference: clinicaltrials:NCT01764633
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The primary objective was to evaluate the effect of treatment with evolocumab, compared with placebo, on the risk for cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in patients with clinically evident cardiovascular disease.
    explanation: Supports PCSK9 inhibition as a trial-validated approach for reducing cardiovascular risk in dyslipidemic high-risk populations.
- name: NCT01663402
  phase: PHASE_III
  status: COMPLETED
  description: >
    ODYSSEY OUTCOMES trial evaluating alirocumab versus placebo after recent
    acute coronary syndrome in participants receiving evidence-based dyslipidemia
    management.
  target_phenotypes:
  - preferred_term: Increased LDL cholesterol concentration
    term:
      id: HP:0003141
      label: Increased LDL cholesterol concentration
  - preferred_term: Coronary artery atherosclerosis
    term:
      id: HP:0001677
      label: Coronary artery atherosclerosis
  evidence:
  - reference: clinicaltrials:NCT01663402
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: To compare the effect of alirocumab with placebo on the occurrence of cardiovascular (CV) events (composite endpoint of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and non-fatal ischemic stroke, unstable angina (UA) requiring hospitalization) in participants who experienced an acute coronary syndrome (ACS) event 4 to 52 weeks prior to randomization and were treated with evidence-based medical and dietary management of dyslipidemia.
    explanation: Supports clinical use of a PCSK9 monoclonal antibody in high-risk dyslipidemia with recent ACS.
- name: NCT02993406
  phase: PHASE_III
  status: COMPLETED
  description: >
    CLEAR Outcomes trial assessing whether bempedoic acid lowers major
    cardiovascular events in statin-intolerant participants with or at high risk
    for cardiovascular disease.
  target_phenotypes:
  - preferred_term: Increased LDL cholesterol concentration
    term:
      id: HP:0003141
      label: Increased LDL cholesterol concentration
  - preferred_term: Coronary artery atherosclerosis
    term:
      id: HP:0001677
      label: Coronary artery atherosclerosis
  evidence:
  - reference: clinicaltrials:NCT02993406
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in participants who have or are at high risk for cardiovascular disease and are statin intolerant.
    explanation: Supports bempedoic acid as an evidence-based option for LDL management in statin-intolerant populations.
- name: NCT05355402
  phase: PHASE_II
  status: COMPLETED
  description: >
    Phase 2b trial of olezarsen in hypertriglyceridemia (including severe
    hypertriglyceridemia) assessing triglyceride lowering and broader
    apolipoprotein/lipoprotein changes.
  target_phenotypes:
  - preferred_term: Hypertriglyceridemia
    term:
      id: HP:0002155
      label: Hypertriglyceridemia
  evidence:
  - reference: clinicaltrials:NCT05355402
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The purpose of the study was to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo at Months 6 and 12 and the proportion of participants who achieve different thresholds in fasting TG.
    explanation: Supports ApoC-III antisense therapy development for severe triglyceride-driven hyperlipidemia.

📚

References & Deep Research

Deep Research

1

Falcon ▸

Disease Pathophysiology Research Template

Edison Scientific Literature 38 citations 2026-03-03T17:31:04.620206

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

Disease Name: Hyperlipidemia
MONDO ID: (if available)
Category: Complex

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Hyperlipidemia. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

What are the primary pathophysiological mechanisms?
What molecular pathways are dysregulated?
What cellular processes are affected?

2. Key Molecular Players

Genes/Proteins: Which genes are causally involved or implicated?
Chemical Entities: What metabolites, drugs, or small molecules are relevant?
Cell Types: Which cell types are primarily affected?
Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

What biological processes (GO terms) are disrupted?
Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

Where in the cell do key processes occur?
Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

What is the sequence of events from initial trigger to clinical manifestation?
Are there distinct stages or phases?

6. Phenotypic Manifestations

What are the key clinical phenotypes?
How do they relate to the underlying mechanisms?

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic claims
Prioritize recent reviews and landmark papers
Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Pathophysiology Research Report: Hyperlipidemia (Complex)

Disease identifiers

Disease name: Hyperlipidemia
MONDO ID: MONDO:0021187 (hyperlipidemia) (Open Targets disease mapping in tool output; MONDO shown explicitly) (solnica20242024guidelinesof pages 1-2)
Related HPO concept (phenotype, not disease): HP:0003077 Hyperlipidemia (shown in Open Targets mapping output) (solnica20242024guidelinesof pages 1-2)

1) Key concepts and definitions (current understanding)

Hyperlipidemia is a disorder of elevated circulating lipids and/or lipoproteins, commonly manifesting as increased apoB-containing atherogenic particles (LDL, VLDL remnants) and/or triglyceride-rich lipoproteins (TRLs) (VLDL, chylomicrons and remnants). Mechanistically, hyperlipidemia reflects imbalance among (i) hepatic/intestinal lipoprotein production, (ii) intravascular lipolysis and remodeling, and (iii) hepatic clearance by receptor-mediated pathways; downstream, excess apoB particles drive arterial wall retention, oxidation, foam-cell formation, and inflammation.

A key contemporary refinement is the concept of residual lipid risk: even after intensive LDL-C lowering, TRLs/remnants, Lp(a), and impaired cholesterol efflux can sustain atherothrombotic risk. This is emphasized in recent hypertriglyceridemia syntheses reporting LDL-C–independent residual risk from elevated TG/TRLs (scicchitano2024hypertriglyceridemiamolecularand pages 1-2).

2) Core pathophysiology (molecular pathways and dysregulated cellular processes)

2.1 ApoB/LDL axis: impaired clearance + vascular retention

LDLR–PCSK9 axis (hepatic clearance): PCSK9 regulates circulating LDL-C primarily by promoting LDL receptor (LDLR) degradation. A 2024 primary mechanistic study in Nature Communications summarizes the canonical concept: “PCSK9 binds to and degrades low-density lipoprotein (LDL) receptor, leading to increase of LDL cholesterol in blood” (published 2024-03; https://doi.org/10.1038/s41467-024-46336-2) (shin2024pcsk9stimulatessyk pages 1-2).

Arterial wall injury initiation: Excess LDL-C contributes to foam-cell formation and plaque inflammation; the same study notes: “Excessive LDL-C in the blood infiltrates the sub-endothelial layer and is oxidized… resulting in foam cell formation, vascular inflammation, and atherosclerosis” (shin2024pcsk9stimulatessyk pages 1-2).

2.2 LDLR-independent inflammatory signaling by PCSK9 (newer mechanistic insight)

A major 2024 development is evidence that PCSK9 can promote vascular inflammation independently of LDLR, via a receptor/signaling complex in immune and vascular cells. Shin et al. report: “PCSK9 itself directly induces inflammation and aggravates atherosclerosis independently of the LDL receptor” and identify CAP1 as the binding partner: “CAP1 is the main binding partner of PCSK9…” with downstream mediators “Syk” and “PKCδ” and NF-κB activation (shin2024pcsk9stimulatessyk pages 1-2).

They further connect PCSK9→CAP1 to innate immune patterning and lipid uptake: PCSK9/CAP1 signaling includes “induction of cytokines, Toll like receptor 4, and scavenger receptors, enhancing the uptake of oxidized LDL” (shin2024pcsk9stimulatessyk pages 1-2). Dose-response evidence is shown in human monocytes/endothelial cells: “rhPCSK9… induced p65 phosphorylation… in a dose-dependent manner” and increased inflammatory cytokine transcripts (TNF-α, IL-1β, IL-6) and adhesion molecules (VCAM1, ICAM1, SELE) (shin2024pcsk9stimulatessyk pages 2-3).

Implication: Hyperlipidemia pathophysiology is not purely a “lipid transport” disorder; in at least some contexts it includes a feed-forward immunometabolic loop in which lipid-regulatory proteins (e.g., PCSK9) directly modulate vascular inflammation.

2.3 TRL/TG axis: overproduction, impaired lipolysis, impaired remnant clearance

TRL metabolism: TRLs are primarily VLDL (liver-derived) and chylomicrons (intestine-derived), which deliver triglycerides to tissues and are converted to remnants via lipoprotein lipase (LPL) and other enzymes. Chen et al. (2024-01; https://doi.org/10.1186/s12944-023-01993-y) summarize that this regulation is “predominantly governed by ANGPTL4/3/8” (chen2024unlockingthemysteries pages 1-2).

ApoC-III as a central inhibitor of TRL clearance: Multiple recent sources converge that APOC3/apoC-III inhibits LPL-mediated lipolysis and suppresses hepatic remnant clearance. - Mechanistic definition (review): “ApoC-III is a well-known inhibitor of LPL” and contributes to decreased VLDL clearance in hypertriglyceridemia via an apoC-III–dominated TRL state (Giammanco et al., 2023-01-23 online; https://doi.org/10.1007/s11883-023-01080-8) (giammanco2023apociiiagatekeeper pages 1-2). - Concise mechanism (trial intro): “ApoC-III downregulates lipoprotein metabolism by inhibiting lipoprotein and hepatic lipases and by reducing hepatic uptake of TRLs via low-density lipoprotein (LDL) and LDL receptor-related protein receptors” (Karwatowska‑Prokopczuk et al., 2024-10; https://doi.org/10.1186/s12944-024-02297-5) (karwatowskaprokopczuk2024efficacyandsafety pages 1-2).

VLDL assembly/biogenesis (intracellular lipidation pathway): Hepatic VLDL secretion depends on apoB availability and ER lipidation. - “The biosynthesis of VLDL is a multistep process that begins in the rough endoplasmic reticulum (RER)” (chen2024unlockingthemysteries pages 1-2). - “Hepatic VLDL assembly starts with the cotranslational translocation of APOB… where microsomal triglyceride transfer protein (MTP) helps in the first lipid decoration of APOB” (chen2024unlockingthemysteries pages 1-2). - “Without sufficient lipidation, nascent APOB is degraded” (chen2024unlockingthemysteries pages 1-2).

These steps represent actionable nodes for therapy (e.g., MTP inhibition; apoB synthesis inhibition; ANGPTL3 inhibition) (chen2024unlockingthemysteries pages 1-2).

2.4 Foam cell biology and impaired reverse cholesterol transport (RCT)

Atherogenesis emerges when cholesterol uptake exceeds efflux in vascular cells—especially macrophages. Albitar et al. (2024-07; https://doi.org/10.3390/nu16132156) describe macrophage foam-cell formation and intracellular handling: - “Lipids engulfed through phagocytosis… [enter] lysosomes. Lysosomes break down cholesteryl esters to release free cholesterol. This free cholesterol is then… modified by… ACAT1… reserved inside the cell, particularly in the ER” (albitar2024effectsoflipoproteins pages 5-7). - In lesions, “Following the development of atherosclerosis, elevated levels of ACAT1 and reduced expression of NCEH result in the macrophage’s overload with cholesterol” (albitar2024effectsoflipoproteins pages 5-7).

They also situate RCT as a protective pathway controlled by nuclear receptor/transporter programs: “RCT… is controlled by the X receptor (LXR) of the liver, along with… ABCA1 and ABCG1” (albitar2024effectsoflipoproteins pages 5-7).

3) Key molecular players (genes/proteins), cell types, and tissues

3.1 Gene/protein annotations (HGNC symbols; selected)

Core LDL/apoB metabolism and clearance - LDLR (low density lipoprotein receptor): hepatic endocytosis/clearance of LDL; genetically implicated in familial hypercholesterolemia (FH) (abbasi2024newinsightsinto pages 1-2). - PCSK9: promotes LDLR degradation; additionally promotes LDLR-independent inflammation via CAP1→Syk/PKCδ→NF-κB (shin2024pcsk9stimulatessyk pages 1-2, shin2024pcsk9stimulatessyk pages 2-3). - APOB: structural protein of VLDL/LDL; required for VLDL assembly and secretion; dependent on MTP-mediated lipidation (chen2024unlockingthemysteries pages 1-2). - MTTP (MTP): microsomal triglyceride transfer protein; lipidates apoB in the ER during VLDL biogenesis (chen2024unlockingthemysteries pages 1-2).

Core TRL/TG metabolism - LPL: hydrolyzes TG in TRLs (contextualized as central regulator in ApoC-III review) (giammanco2023apociiiagatekeeper pages 1-2). - APOC3: inhibits LPL and reduces hepatic uptake of TRLs via LDLR/LRP receptors; shifts TRL clearance kinetics toward slower, apoC-III–dominated clearance in hypertriglyceridemia (karwatowskaprokopczuk2024efficacyandsafety pages 1-2, giammanco2023apociiiagatekeeper pages 1-2). - ANGPTL3/ANGPTL4/ANGPTL8: regulators of TRL metabolism and LPL activity (chen2024unlockingthemysteries pages 1-2).

Cholesterol efflux/foam-cell biology - ABCA1, ABCG1 (ATP-binding cassette transporters): cholesterol efflux in RCT program under LXR control (albitar2024effectsoflipoproteins pages 5-7). - ACAT1 (acetyl-CoA acetyltransferase 1; SOAT1 commonly used synonym in lipid literature): re-esterifies free cholesterol in ER, promoting cholesterol storage/foam phenotype when dysregulated (albitar2024effectsoflipoproteins pages 5-7).

3.2 Cell types (CL) most implicated

Hepatocytes (CL:0000182): apoB-containing VLDL production; PCSK9 production; LDLR-mediated clearance. Liver identified as major PCSK9 source in vivo adenoviral model (shin2024pcsk9stimulatessyk pages 2-3).
Monocytes (CL:0000576), macrophages (CL:0000235): oxLDL uptake, foam-cell formation; PCSK9-induced inflammatory signaling and cytokine induction; macrophage infiltration into plaques increased with PCSK9 overexpression (shin2024pcsk9stimulatessyk pages 2-3, albitar2024effectsoflipoproteins pages 5-7).
Vascular endothelial cells (CL:0000115): respond to PCSK9 with increased adhesion molecules (VCAM1/ICAM1/SELE) and inflammatory transcripts (shin2024pcsk9stimulatessyk pages 2-3).
Vascular smooth muscle cells (CL:0000192): participate in oxidative milieu and plaque biology (noted as ROS sources contributing to LDL oxidation) (shin2024pcsk9stimulatessyk pages 1-2).

3.3 Anatomical locations (UBERON)

Liver (UBERON:0002107): VLDL secretion; PCSK9 production; LDLR-mediated clearance (shin2024pcsk9stimulatessyk pages 2-3, chen2024unlockingthemysteries pages 1-2).
Arterial wall / carotid artery (UBERON:0001577) and coronary arteries: LDL infiltration/oxidation, plaque inflammation; clinical correlates of severe hyperlipidemia show arterial stenosis/calcification (shin2024pcsk9stimulatessyk pages 1-2, guan2024lipoproteinapheresisan pages 2-5).
Adipose tissue (UBERON:0001013) and skeletal muscle (UBERON:0001134): TRL fatty acid delivery (VLDL fasting delivery to muscle; chylomicrons to adipose described in TRL overview) (chen2024unlockingthemysteries pages 1-2).

3.4 Chemical entities (CHEBI; examples relevant to mechanisms)

Cholesterol (CHEBI:16113); cholesteryl ester (CHEBI class); triglycerides / triacylglycerols (CHEBI:17855); fatty acids (CHEBI class); oxidized LDL components (e.g., oxidized phospholipids, CHEBI class).
Therapeutic small molecules/biologics relevant to mechanisms include statins (HMG-CoA reductase inhibitors), ezetimibe, bempedoic acid, PCSK9 inhibitors, inclisiran (siRNA), evinacumab (anti-ANGPTL3), and APOC3 antisense oligonucleotides (olezarsen) (abbasi2024newinsightsinto pages 1-2, banach20242024recommendationson pages 1-2, karwatowskaprokopczuk2024efficacyandsafety pages 1-2).

4) Biological processes (GO) and cellular components (GO CC) disrupted (knowledge-base oriented)

GO Biological Process (selected, pathophysiology-aligned)

Lipoprotein metabolic process; cholesterol transport; triglyceride catabolic process (TRL lipolysis);
receptor-mediated endocytosis (LDLR-dependent clearance);
very-low-density lipoprotein particle assembly (apoB/MTP-dependent VLDL biogenesis);
cholesterol efflux and reverse cholesterol transport (ABCA1/ABCG1/SR-B1 pathways) (albitar2024effectsoflipoproteins pages 5-7);
inflammatory response and NF-κB signaling (PCSK9→CAP1→Syk/PKCδ→p65 phosphorylation; cytokine induction) (shin2024pcsk9stimulatessyk pages 1-2, shin2024pcsk9stimulatessyk pages 2-3);
cell adhesion molecule expression / leukocyte recruitment (VCAM1/ICAM1 induction) (shin2024pcsk9stimulatessyk pages 2-3).

GO Cellular Component (selected)

Rough endoplasmic reticulum / endoplasmic reticulum membrane (VLDL assembly; apoB lipidation) (chen2024unlockingthemysteries pages 1-2).
Lysosome (cholesteryl ester hydrolysis to free cholesterol in macrophages) (albitar2024effectsoflipoproteins pages 5-7).
Endoplasmic reticulum (re-esterification via ACAT1; cholesterol storage) (albitar2024effectsoflipoproteins pages 5-7).
Plasma membrane (CAP1 localization and PCSK9-CAP1 colocalization; scavenger receptors; adhesion molecules) (shin2024pcsk9stimulatessyk pages 2-3).
Extracellular space / blood plasma (circulating lipoproteins, PCSK9) (shin2024pcsk9stimulatessyk pages 1-2).

5) Disease progression model (sequence from trigger to clinical manifestation)

Initiating drivers: genetic variants (e.g., LDLR/APOB/PCSK9; APOC3; LPL pathway genes) and/or metabolic drivers (insulin resistance, diet, obesity) increase apoB particle production and/or impair clearance (abbasi2024newinsightsinto pages 1-2, giammanco2023apociiiagatekeeper pages 1-2).
Overproduction / impaired processing:
Hepatic VLDL production increases when apoB is lipidated efficiently; apoB that is insufficiently lipidated is degraded, linking secretion to intrahepatic lipid availability and MTP function (chen2024unlockingthemysteries pages 1-2).
TRL hydrolysis is slowed when APOC3 is high and when ANGPTL regulators inhibit lipolysis (karwatowskaprokopczuk2024efficacyandsafety pages 1-2, chen2024unlockingthemysteries pages 1-2).
Particle persistence and arterial entry: Excess apoB particles infiltrate subendothelial space; oxidation occurs in ROS-rich environments involving macrophages/ECs/SMCs, promoting foam cells and inflammation (shin2024pcsk9stimulatessyk pages 1-2).
Foam-cell formation and defective efflux: macrophage uptake of modified lipoproteins drives lysosomal hydrolysis and ER re-esterification; increased ACAT1 and reduced NCEH promote cholesterol ester accumulation and foam phenotype; RCT dysfunction limits protective efflux (albitar2024effectsoflipoproteins pages 5-7).
Inflammation amplification:
Lipid-driven sterile inflammation proceeds via cytokines and adhesion molecule induction.
PCSK9 may amplify inflammation independently of LDLR via CAP1 and NF-κB pathway activation, increasing TLR4/scavenger receptor expression and oxLDL uptake (shin2024pcsk9stimulatessyk pages 1-2, shin2024pcsk9stimulatessyk pages 2-3).
Clinical manifestations: ASCVD events (MI, stroke, PAD), valve disease and arterial stenosis in severe familial disease; pancreatitis in severe hypertriglyceridemia/chylomicronemia (abbasi2024newinsightsinto pages 1-2, guan2024lipoproteinapheresisan pages 2-5, karwatowskaprokopczuk2024efficacyandsafety pages 1-2).

6) Phenotypic manifestations (HP; examples) and mechanistic links

Major clinical phenotypes (examples; mapable to HPO)

Hyperlipidemia (HP:0003077) (disease-phenotype mapping in Open Targets output) (solnica20242024guidelinesof pages 1-2)
Atherosclerotic cardiovascular disease / coronary artery disease, myocardial infarction, stroke, peripheral arterial disease (phenotype terms explicitly listed) (abbasi2024newinsightsinto pages 1-2)
Xanthomas (cutaneous/tendon; seen in severe familial hypercholesterolemia) (guan2024lipoproteinapheresisan pages 2-5)
Pancreatitis (in FCS and severe hypertriglyceridemia; mechanistically from chylomicronemia/TRL overload) (karwatowskaprokopczuk2024efficacyandsafety pages 1-2)

Quantitative phenotype-linked thresholds and risk

Severe hypertriglyceridemia defined as TG ≥500 mg/dL; hypertriglyceridemia category 150–499 mg/dL (karwatowskaprokopczuk2024efficacyandsafety pages 1-2).
In PESA, TG ≥150 mg/dL associated with 35% increase in subclinical noncoronary atherosclerosis risk (scicchitano2024hypertriglyceridemiamolecularand pages 1-2).

7) Recent developments (prioritizing 2023–2024)

7.1 PCSK9 biology expanded beyond LDLR recycling

The 2024 Nature Communications work extends PCSK9 from LDLR degradation into direct inflammatory signaling: “PCSK9 itself directly induces inflammation… independently of the LDL receptor” (shin2024pcsk9stimulatessyk pages 1-2) and mechanistically ties to CAP1 and NF-κB phosphorylation/cytokine induction (shin2024pcsk9stimulatessyk pages 2-3). This helps explain why PCSK9 modulation could influence plaque biology beyond LDL-C reduction.

7.2 Next-generation TRL therapeutics targeting ApoC-III

ApoC-III targeting is now supported by human early-phase data. In a phase 1 trial, olezarsen (GalNAc3-conjugated hepatic-targeted ASO) significantly reduced apoC-III and triglycerides: in multiple-dose cohort, “percentage reduction in apoC-III/TG was −81.6/−73.8%” at day 92 versus placebo reductions (published 2024-10; https://doi.org/10.1186/s12944-024-02297-5) (karwatowskaprokopczuk2024efficacyandsafety pages 1-2). The study also explicitly frames clinical relevance to pancreatitis: FCS is “primarily associated with pancreatitis” and severe HTG associated with both pancreatitis and CVD (karwatowskaprokopczuk2024efficacyandsafety pages 1-2).

7.3 LDLR-independent lipid lowering via ANGPTL3 inhibition

Evinacumab (anti-ANGPTL3) is described as an FDA-approved therapy for HoFH that lowers LDL-C via “an LDL receptor–independent mechanism” with a case report showing 53.4% time-averaged LDL-C reduction after 12 months (published 2023-05; https://doi.org/10.1210/jcemcr/luad058) (chen2024unlockingthemysteries pages 10-11).

7.4 Increased emphasis on VLDL/TRL production and trafficking as causal targets

A 2024 conceptual review highlights VLDL (precursor of LDL) and notes that interventions targeting VLDL production or metabolism “independent of the LDL receptor” may decrease cholesterol levels and provide benefits beyond LDL-centric therapy (chen2024unlockingthemysteries pages 1-2). Figures summarizing these pathways are provided in the paper (Fig. 2 and Fig. 3) (chen2024unlockingthemysteries media aecdd5d3, chen2024unlockingthemysteries media 24e615f7).

8) Current applications and real-world implementations (guidelines/position papers and clinical practice)

8.1 LDL-C goal attainment remains poor (implementation gap)

2023 expert review reports: “In 2023 there are still even 75% of patients over the LDL-C target” and “almost 4 million deaths per year are attributed to LDL-C” (published online 2023-11-02; https://doi.org/10.5114/aoms/174743) (banach20232023theyear pages 1-2).
2024 diagnostic guideline notes lipid disorders are common (“even 70%”) and “worst monitored,” with “only 1/4 of patients… on the LDL-C goal” in Poland/CEE (published online 2024-03-18; https://doi.org/10.5114/aoms/186191) (solnica20242024guidelinesof pages 1-2).
2024 ILEP position paper highlights that in practice goals are unmet “even in 70%” and that “four out of five very high- and extremely high-risk patients” may not achieve LDL targets (published online 2024-11-04; https://doi.org/10.1007/s40265-024-02105-5) (banach20242024recommendationson pages 1-2).

8.2 Clinical implementation examples (real-world)

Lipoprotein apheresis: A 2024 case report illustrates real-world use of double filtration plasmapheresis (DFPP) in refractory HoFH with ~82% LDL-C reduction (13.82→2.43 mmol/L) and clinical stabilization/regression of xanthomas (published 2024-10; https://doi.org/10.1186/s12959-024-00657-w) (guan2024lipoproteinapheresisan pages 2-5).
ApoC-III ASO (olezarsen): early clinical trials show large TG reductions and favorable changes in VLDL-C/apoB/HDL-C, supporting movement toward targeted TRL therapy (karwatowskaprokopczuk2024efficacyandsafety pages 1-2).

9) Relevant statistics and recent study data (selected)

Disease burden and care gaps

Hyperlipidemia attributed burden: 29.7 million DALYs and 2.6 million deaths reported in a 2024 review (https://doi.org/10.7759/cureus.63078; 2024-06) (abbasi2024newinsightsinto pages 1-2).
LDL-C target attainment: ~75% above LDL-C target (2023) (banach20232023theyear pages 1-2); 1/4 on LDL-C goal in Poland/CEE (2024) (solnica20242024guidelinesof pages 1-2).

TRL/TG risk

Hypertriglyceridemia CHD risk cited as 57–76% range in a 2024 review (published 2024-06-08; https://doi.org/10.3390/ijms25126364) (scicchitano2024hypertriglyceridemiamolecularand pages 1-2).
TG ≥150 mg/dL associated with 35% increased subclinical noncoronary atherosclerosis risk (PESA cited) (scicchitano2024hypertriglyceridemiamolecularand pages 1-2).

Effect sizes for emerging therapies

Olezarsen (ASO anti-APOC3): multiple-dose cohort achieved −81.6% apoC-III and −73.8% TG at day 92 (karwatowskaprokopczuk2024efficacyandsafety pages 1-2).
Evinacumab (anti-ANGPTL3) in HoFH case: 53.4% time-averaged LDL-C reduction over 12 months (chen2024unlockingthemysteries pages 10-11).

10) Expert opinion synthesis (authoritative sources)

Recent expert position papers emphasize that LDL-C lowering remains foundational (“lower is better for longer” and “earlier the better”), but that real-world attainment is inadequate and that combination and next-generation therapies are needed for high-risk groups (banach20242024recommendationson pages 1-2). Complementary diagnostic guidelines stress standardized lipid profiling and expanded targets (e.g., non-HDL-C, remnants/small dense LDL) to improve early detection and monitoring (solnica20242024guidelinesof pages 1-2).

11) Knowledge-base-ready structured annotations

11.1 Entity summary table (mechanism-centered)

Module	Key HGNC genes/proteins	Core mechanism (1–2 lines)	Key cell types (CL)	Key tissues (UBERON)	Key cellular components	Evidence
LDL-C/apoB clearance	LDLR, PCSK9	PCSK9 promotes LDLR degradation, raising LDL-C; LDL infiltrates subendothelium → oxidation → foam cells/inflammation	hepatocyte; monocyte/macrophage; EC; SMC	liver; artery	plasma membrane; extracellular space	Shin 2024 Nat Commun (doi:10.1038/s41467-024-46336-2) (shin2024pcsk9stimulatessyk pages 1-2)
PCSK9 inflammatory signaling (LDLR-independent)	PCSK9, CAP1, SYK, PRKCD (PKCδ), NFKB (p65), TLR4	PCSK9–CAP1 binding activates Syk/PKCδ and NF-κB, induces cytokines/adhesion molecules, increases scavenger receptors and oxLDL uptake	monocyte/macrophage; EC	artery; immune system	plasma membrane; cytosol/nucleus	Shin 2024 (shin2024pcsk9stimulatessyk pages 1-2, shin2024pcsk9stimulatessyk pages 2-3)
TRL/TG metabolism	APOC3, LPL, ANGPTL3/4/8	ANGPTL3/4/8 regulate TRL processing; ApoC-III inhibits LPL and reduces hepatic TRL uptake via LDLR/LRP receptors	hepatocyte; adipocyte; myocyte; macrophage	liver; adipose; muscle	capillary lumen/extracellular; lipoprotein particles	Chen 2024 (doi:10.1186/s12944-023-01993-y) (chen2024unlockingthemysteries pages 1-2); Karwatowska‑Prokopczuk 2024 (karwatowskaprokopczuk2024efficacyandsafety pages 1-2); Giammanco 2023 (giammanco2023apociiiagatekeeper pages 1-2)
VLDL production/trafficking	APOB, MTTP	VLDL assembly begins in rough ER; MTP lipidates apoB; insufficient lipidation → apoB degradation; secretion drives TRL burden	hepatocyte	liver	rough ER; secretory pathway	Chen 2024 (chen2024unlockingthemysteries pages 1-2); Fig. 2 visual (chen2024unlockingthemysteries media aecdd5d3)
Foam cells & RCT	LXR, ABCA1, ABCG1, APOE, ACAT1	Lysosomal CE hydrolysis → free cholesterol; ER re-esterification via ACAT1; transporter downregulation with scavenger receptor upregulation → foam cells; RCT under LXR/ABCA1/ABCG1	macrophage; vascular cells	arterial intima; liver	lysosome; ER; plasma membrane	Albitar 2024 Nutrients (doi:10.3390/nu16132156) (albitar2024effectsoflipoproteins pages 5-7)

11.2 Drugs/chemical interventions linked to mechanisms (examples)

PCSK9 inhibition (mAbs; siRNA inclisiran): increases LDLR-mediated clearance; may not fully address PCSK9’s LDLR-independent inflammatory actions depending on mechanism (concept implied by PCSK9 inflammatory signaling study) (shin2024pcsk9stimulatessyk pages 1-2, shin2024pcsk9stimulatessyk pages 2-3).
ApoC-III inhibition (olezarsen): reduces apoC-III/TG; targets hepatic apoC-III production with GalNAc delivery (karwatowskaprokopczuk2024efficacyandsafety pages 1-2).
ANGPTL3 inhibition (evinacumab): LDLR-independent LDL-C lowering in HoFH (chen2024unlockingthemysteries pages 10-11).
Apheresis (DFPP): acute removal of LDL-C/Lp(a) in refractory FH (guan2024lipoproteinapheresisan pages 2-5).

12) Evidence items (with identifiers)

Note: Many journal excerpts retrieved here include DOI/URL and dates but not PMIDs in-text; where PMIDs are not present in the retrieved content, DOI/URL-based citation is provided.

Shin D, et al. PCSK9 stimulates Syk, PKCδ, and NF-κB… independently of LDL receptor. Nature Communications. Accepted 2024-02-23. DOI/URL: https://doi.org/10.1038/s41467-024-46336-2. Key quote: “PCSK9 itself directly induces inflammation…” (shin2024pcsk9stimulatessyk pages 1-2, shin2024pcsk9stimulatessyk pages 2-3).
Chen J, et al. Unlocking the mysteries of VLDL. Lipids in Health and Disease. 2024-01. DOI/URL: https://doi.org/10.1186/s12944-023-01993-y. Key quote: VLDL assembly begins in rough ER; MTP lipidates apoB (chen2024unlockingthemysteries pages 1-2). Figures summarizing pathways (chen2024unlockingthemysteries media aecdd5d3, chen2024unlockingthemysteries media 24e615f7).
Giammanco A, et al. APOC-III: a Gatekeeper. Current Atherosclerosis Reports. Published online 2023-01-23. DOI/URL: https://doi.org/10.1007/s11883-023-01080-8. Key quote: “ApoC-III is a well-known inhibitor of LPL…” (giammanco2023apociiiagatekeeper pages 1-2).
Albitar O, et al. Effects of Lipoproteins on Metabolic Health. Nutrients. 2024-07. DOI/URL: https://doi.org/10.3390/nu16132156. Key quote: lysosomal CE hydrolysis, ACAT1 re-esterification in ER, foam cell overload with high ACAT1/low NCEH (albitar2024effectsoflipoproteins pages 5-7).
Karwatowska‑Prokopczuk E, et al. Olezarsen phase 1. Lipids in Health and Disease. 2024-10. DOI/URL: https://doi.org/10.1186/s12944-024-02297-5. Quantitative reductions in apoC-III/TG and thresholds defining SHTG (karwatowskaprokopczuk2024efficacyandsafety pages 1-2).
Banach M, et al. ILEP position paper. Drugs. Published online 2024-11-04. DOI/URL: https://doi.org/10.1007/s40265-024-02105-5. LDL-C goal attainment gaps (banach20242024recommendationson pages 1-2).

References

(solnica20242024guidelinesof pages 1-2): Bogdan Solnica, Grażyna Sygitowicz, Dariusz Sitkiewicz, Jacek Jóźwiak, Sławomir Kasperczyk, Marlena Broncel, Anna Wolska, Grażyna Odrowąż-Sypniewska, and Maciej Banach. 2024 guidelines of the polish society of laboratory diagnostics and the polish lipid association on laboratory diagnostics of lipid metabolism disorders. Archives of Medical Science : AMS, 20:357-374, Mar 2024. URL: https://doi.org/10.5114/aoms/186191, doi:10.5114/aoms/186191. This article has 41 citations.
(scicchitano2024hypertriglyceridemiamolecularand pages 1-2): Pietro Scicchitano, Francesca Amati, Marco Matteo Ciccone, Flavio D’Ascenzi, Egidio Imbalzano, Riccardo Liga, Stefania Paolillo, Maria Concetta Pastore, Andrea Rinaldi, Anna Vittoria Mattioli, and Matteo Cameli. Hypertriglyceridemia: molecular and genetic landscapes. International Journal of Molecular Sciences, 25:6364, Jun 2024. URL: https://doi.org/10.3390/ijms25126364, doi:10.3390/ijms25126364. This article has 13 citations.
(shin2024pcsk9stimulatessyk pages 1-2): Dasom Shin, Soungchan Kim, Hwan Lee, Hyun-Chae Lee, Jaewon Lee, Hyun-woo Park, Mina Fukai, EunByule Choi, Subin Choi, Bon-Jun Koo, Ji-Hoon Yu, Gyurae No, Sungyoon Cho, Chan Woo Kim, Dohyun Han, Hyun-Duk Jang, and Hyo-Soo Kim. Pcsk9 stimulates syk, pkcδ, and nf-κb, leading to atherosclerosis progression independently of ldl receptor. Nature Communications, Mar 2024. URL: https://doi.org/10.1038/s41467-024-46336-2, doi:10.1038/s41467-024-46336-2. This article has 53 citations and is from a highest quality peer-reviewed journal.
(shin2024pcsk9stimulatessyk pages 2-3): Dasom Shin, Soungchan Kim, Hwan Lee, Hyun-Chae Lee, Jaewon Lee, Hyun-woo Park, Mina Fukai, EunByule Choi, Subin Choi, Bon-Jun Koo, Ji-Hoon Yu, Gyurae No, Sungyoon Cho, Chan Woo Kim, Dohyun Han, Hyun-Duk Jang, and Hyo-Soo Kim. Pcsk9 stimulates syk, pkcδ, and nf-κb, leading to atherosclerosis progression independently of ldl receptor. Nature Communications, Mar 2024. URL: https://doi.org/10.1038/s41467-024-46336-2, doi:10.1038/s41467-024-46336-2. This article has 53 citations and is from a highest quality peer-reviewed journal.
(chen2024unlockingthemysteries pages 1-2): Jingfei Chen, Zhenfei Fang, Qin Luo, Xiao Wang, Mohamad Warda, Avash Das, Federico Oldoni, and Fei Luo. Unlocking the mysteries of vldl: exploring its production, intracellular trafficking, and metabolism as therapeutic targets. Lipids in Health and Disease, Jan 2024. URL: https://doi.org/10.1186/s12944-023-01993-y, doi:10.1186/s12944-023-01993-y. This article has 47 citations and is from a peer-reviewed journal.
(giammanco2023apociiiagatekeeper pages 1-2): Antonina Giammanco, Rossella Spina, Angelo B. Cefalù, and Maurizio Averna. Apoc-iii: a gatekeeper in controlling triglyceride metabolism. Current Atherosclerosis Reports, 25:67-76, Jan 2023. URL: https://doi.org/10.1007/s11883-023-01080-8, doi:10.1007/s11883-023-01080-8. This article has 75 citations and is from a peer-reviewed journal.
(karwatowskaprokopczuk2024efficacyandsafety pages 1-2): Ewa Karwatowska-Prokopczuk, Anastasia Lesogor, Jing-He Yan, Angelika Hoenlinger, Alison Margolskee, Lu Li, and Sotirios Tsimikas. Efficacy and safety of olezarsen in lowering apolipoprotein c-iii and triglycerides in healthy japanese americans. Lipids in Health and Disease, Oct 2024. URL: https://doi.org/10.1186/s12944-024-02297-5, doi:10.1186/s12944-024-02297-5. This article has 15 citations and is from a peer-reviewed journal.
(albitar2024effectsoflipoproteins pages 5-7): Obaida Albitar, Crystal M. D’Souza, and Ernest A. Adeghate. Effects of lipoproteins on metabolic health. Nutrients, 16:2156, Jul 2024. URL: https://doi.org/10.3390/nu16132156, doi:10.3390/nu16132156. This article has 31 citations.
(abbasi2024newinsightsinto pages 1-2): Seema Abbasi, Adnan Khan, and Muhammad W Choudhry. New insights into the treatment of hyperlipidemia: pharmacological updates and emerging treatments. Cureus, Jun 2024. URL: https://doi.org/10.7759/cureus.63078, doi:10.7759/cureus.63078. This article has 26 citations.
(guan2024lipoproteinapheresisan pages 2-5): Mingjing Guan, Hao Wang, Fang Wang, Shichu Liang, Li Ling, Bo Wang, and Ling Zhang. Lipoprotein apheresis: an established therapeutic modality for homozygous familial hypercholesterolemia patients refractory to pcsk9 inhibitors: a case report and literature review. Thrombosis Journal, Oct 2024. URL: https://doi.org/10.1186/s12959-024-00657-w, doi:10.1186/s12959-024-00657-w. This article has 2 citations and is from a peer-reviewed journal.
(banach20242024recommendationson pages 1-2): Maciej Banach, Željko Reiner, Stanisław Surma, Gani Bajraktari, Agata Bielecka-Dabrowa, Matjaz Bunc, Ibadete Bytyçi, Richard Ceska, Arrigo F. G. Cicero, Dariusz Dudek, Krzysztof Dyrbuś, Jan Fedacko, Zlatko Fras, Dan Gaita, Dov Gavish, Marek Gierlotka, Robert Gil, Ioanna Gouni-Berthold, Piotr Jankowski, Zoltán Járai, Jacek Jóźwiak, Niki Katsiki, Gustavs Latkovskis, Stefania Lucia Magda, Eduard Margetic, Roman Margoczy, Olena Mitchenko, Azra Durak-Nalbantic, Petr Ostadal, Gyorgy Paragh, Zaneta Petrulioniene, Francesco Paneni, Ivan Pećin, Daniel Pella, Arman Postadzhiyan, Anca Pantea Stoian, Matias Trbusic, Cristian Alexandru Udroiu, Margus Viigimaa, Dragos Vinereanu, Charalambos Vlachopoulos, Michal Vrablik, Dusko Vulic, and Peter E. Penson. 2024 recommendations on the optimal use of lipid-lowering therapy in established atherosclerotic cardiovascular disease and following acute coronary syndromes: a position paper of the international lipid expert panel (ilep). Drugs, 84:1541-1577, Nov 2024. URL: https://doi.org/10.1007/s40265-024-02105-5, doi:10.1007/s40265-024-02105-5. This article has 51 citations and is from a domain leading peer-reviewed journal.
(chen2024unlockingthemysteries pages 10-11): Jingfei Chen, Zhenfei Fang, Qin Luo, Xiao Wang, Mohamad Warda, Avash Das, Federico Oldoni, and Fei Luo. Unlocking the mysteries of vldl: exploring its production, intracellular trafficking, and metabolism as therapeutic targets. Lipids in Health and Disease, Jan 2024. URL: https://doi.org/10.1186/s12944-023-01993-y, doi:10.1186/s12944-023-01993-y. This article has 47 citations and is from a peer-reviewed journal.
(chen2024unlockingthemysteries media aecdd5d3): Jingfei Chen, Zhenfei Fang, Qin Luo, Xiao Wang, Mohamad Warda, Avash Das, Federico Oldoni, and Fei Luo. Unlocking the mysteries of vldl: exploring its production, intracellular trafficking, and metabolism as therapeutic targets. Lipids in Health and Disease, Jan 2024. URL: https://doi.org/10.1186/s12944-023-01993-y, doi:10.1186/s12944-023-01993-y. This article has 47 citations and is from a peer-reviewed journal.
(chen2024unlockingthemysteries media 24e615f7): Jingfei Chen, Zhenfei Fang, Qin Luo, Xiao Wang, Mohamad Warda, Avash Das, Federico Oldoni, and Fei Luo. Unlocking the mysteries of vldl: exploring its production, intracellular trafficking, and metabolism as therapeutic targets. Lipids in Health and Disease, Jan 2024. URL: https://doi.org/10.1186/s12944-023-01993-y, doi:10.1186/s12944-023-01993-y. This article has 47 citations and is from a peer-reviewed journal.
(banach20232023theyear pages 1-2): Maciej Banach, Stanisław Surma, and Peter P Toth. 2023: the year in cardiovascular disease - the year of new and prospective lipid lowering therapies. can we render dyslipidemia a rare disease by 2024? Archives of Medical Science, 19:1602-1615, Nov 2023. URL: https://doi.org/10.5114/aoms/174743, doi:10.5114/aoms/174743. This article has 59 citations and is from a peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Environmental Factors

Biochemical Markers

Related Datasets

Clinical Trials

Source YAML

References & Deep Research

Deep Research

Disease Pathophysiology Research Template

Target Disease

Research Objectives

Required Information

1. Core Pathophysiology

2. Key Molecular Players

3. Biological Processes (for GO annotation)

4. Cellular Components

5. Disease Progression

6. Phenotypic Manifestations

Citation Requirements

Output Format

Pathophysiology Research Report: Hyperlipidemia (Complex)

Disease identifiers

1) Key concepts and definitions (current understanding)

2) Core pathophysiology (molecular pathways and dysregulated cellular processes)

2.1 ApoB/LDL axis: impaired clearance + vascular retention

2.2 LDLR-independent inflammatory signaling by PCSK9 (newer mechanistic insight)

2.3 TRL/TG axis: overproduction, impaired lipolysis, impaired remnant clearance

2.4 Foam cell biology and impaired reverse cholesterol transport (RCT)

3) Key molecular players (genes/proteins), cell types, and tissues

3.1 Gene/protein annotations (HGNC symbols; selected)

3.2 Cell types (CL) most implicated

3.3 Anatomical locations (UBERON)

3.4 Chemical entities (CHEBI; examples relevant to mechanisms)

4) Biological processes (GO) and cellular components (GO CC) disrupted (knowledge-base oriented)

GO Biological Process (selected, pathophysiology-aligned)

GO Cellular Component (selected)

5) Disease progression model (sequence from trigger to clinical manifestation)

6) Phenotypic manifestations (HP; examples) and mechanistic links

Major clinical phenotypes (examples; mapable to HPO)

Quantitative phenotype-linked thresholds and risk

7) Recent developments (prioritizing 2023–2024)

7.1 PCSK9 biology expanded beyond LDLR recycling

7.2 Next-generation TRL therapeutics targeting ApoC-III

7.3 LDLR-independent lipid lowering via ANGPTL3 inhibition

7.4 Increased emphasis on VLDL/TRL production and trafficking as causal targets

8) Current applications and real-world implementations (guidelines/position papers and clinical practice)

8.1 LDL-C goal attainment remains poor (implementation gap)

8.2 Clinical implementation examples (real-world)

9) Relevant statistics and recent study data (selected)

Disease burden and care gaps

TRL/TG risk

Effect sizes for emerging therapies

10) Expert opinion synthesis (authoritative sources)

11) Knowledge-base-ready structured annotations

11.1 Entity summary table (mechanism-centered)

11.2 Drugs/chemical interventions linked to mechanisms (examples)

12) Evidence items (with identifiers)